Document:

Exhibit 10.1

THE CONFIDENTIAL PORTION OF THIS EXHIBIT, WHICH
HAVE BEEN REMOVED AND REPLACED WITH AN
ASTERISK, HAVE BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT UNDER RULE 406 PROMULGATED UNDER
THE SECURITIES ACT OF 1933 AND RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934.

                                SUPPLY AGREEMENT
                            SORIN/ELA AND GREATBATCH
                                  2006 - 2010

            Contents:

            1.0  Definitions
            2.0  Product Purchase and Sale
            3.0  Price
            4.0  Orders and Forecasts
            5.0  Warranty and Limitation of Liability
            6.0  Contract Term
            7.0  Business Exit
            8.0  Confidentiality
            9.0  Force Majeure
            10.0     Intellectual Property
            11.0     Miscellaneous
            12.0     Exhibits
                  A.       General Conditions
                  B.       Pricing for Batteries and Capacitors
                  C.       Pricing for Feedthroughs and Filtered Feedthroughs
                  D.       Pricing for Assembled Headers
                  E.       Pricing for Cases
                  F.       Pricing for Miscellaneous Piece Parts
                  G.       Standard Lead Time
                  H.       Audit Process
                  I.       Enclosure Visual Inspection Criteria

<PAGE>

                                Supply Agreement

     THIS AGREEMENT is effective 31 March 2006 and is by and between GREATBATCH,
INC., a New York corporation located at 9645 Wehrle Drive, Clarence, New York,
14031, ("GB") and SORIN/ELA BIOMEDICA CRM and ELA MEDICAL SAS a company located
at 13040 Saluggia (VC), Via Crescentino, Italy ("SORIN/ELA").

     RECITALS: SORIN/ELA wishes to purchase Assembled Headers, Batteries,
Capacitors, Cases, Coated Components, Feedthroughs, Filtered Feedthroughs, and
miscellaneous machined or molded piece parts (hereinafter referred to as
Products) for use in medical devices. GB agrees to manufacture and sell such
Products to SORIN/ELA and/or their Affiliates in accordance with, and subject
to, the specifications and other terms and conditions set forth in the
Agreement.

     NOW, THEREFORE, GB and SORIN/ELA hereby agree as follows:

1.0  DEFINITIONS.
     ------------
     As used in this Agreement, the following defined terms shall
     have the meanings provided for in this Article 1:

     1.1  "Affiliate" means:
             1.1.1 "any other entity/person of which the securities or other
                    ownership interests representing 50% (fifty percent) or more
                    of the equity or 50% (fifty percent) or more of the ordinary
                    voting power or 50% (fifty percent)or more of the general
                    partnership interests are, at the time of such
                    determination, owned, controlled or held, directly or
                    indirectly, by such entity/person, or
             1.1.2  any other entity/person, which at the time of such
                    determination, is controlling, controlled by or under common
                    control with, such entity/person.
             1.1.3  As used herein, the term "control," whether used as a noun
                    or verb, refers to the possession, directly or indirectly,
                    of the power to direct, or cause the direction of, the
                    management or policies of a entity/person, whether through
                    the ownership of voting securities, by contract or
                    otherwise.

     1.2  "Agreement" means this Agreement and all Exhibits hereto and any other
          attachments hereto.

     1.3  "Assembled Headers" means a single piece molded device header
          assembly, including where the context requires all such Products
          manufactured by GB and sold to SORIN/ELA under this Agreement.

     1.4  "Batteries" means lithium iodine low-rate batteries, lithium silver
          vanadium oxide high rate batteries, QHR silver vanadium oxide/carbon
          monofluoride high rate batteries and other power sources, including
          where the context requires all such Products manufactured by GB and
          sold to SORIN/ELA under this Agreement.

                                       2
<PAGE>

     1.5  "Big Four CPA Firm" means Ernst & Young, Deloitte & Touche,
          PricewaterhouseCoopers and KPMG.

     1.6  "Capacitors" means wet tantalum high voltage electrical capacitors,
          including where the context requires all such Products manufactured by
          GB and sold to SORIN/ELA under this Agreement.

     1.7  "Cases" means drawn titanium or stainless steel
          enclosures used in a medical device, including where the context
          requires all such Products manufactured by GB and sold to
          SORIN/ELA under this Agreement.

     1.8  "Change of Control" means the occurrence of any of the following
          events:

             1.8.1  The acquisition by any person of beneficial ownership,
                    directly or indirectly, of securities of GB representing
                    fifty percent (50%) or more of the total voting power
                    represented by GB's then outstanding voting securities;

             1.8.2  A change in the composition of the Board of Directors of GB
                    occurring within a one-year period, as a result of which
                    fewer than a majority of the directors are Incumbent
                    Directors. "Incumbent Directors" shall mean directors who
                    either (i) are directors of GB as of the date hereof, or
                    (ii) are elected, or nominated for election, to the Board of
                    Directors of GB with the affirmative votes of at least a
                    majority of the Incumbent Directors at the time of such
                    election or nomination (but shall not include an individual
                    not otherwise an Incumbent Director whose election or
                    nomination is in connection with an actual or threatened
                    proxy contest relating to the election of directors to GB);

             1.8.3  A merger or consolidation of GB with any other corporation,
                    other than a merger or consolidation which would result in
                    the voting securities of GB outstanding immediately prior
                    thereto continuing to represent (either by remaining
                    outstanding or by being converted into voting securities of
                    the surviving entity) at least fifty percent (50%) of the
                    total voting power represented by the voting securities of
                    GB or such surviving entity outstanding immediately after
                    such merger or consolidation, or the approval by the
                    stockholders of GB of a plan of complete liquidation of GB
                    or of an agreement for the sale or disposition by GB of all
                    or substantially all GB's assets;

             1.8.4  The sale or transfer of all or substantially all of the
                    assets of GB relating to the manufacture of any Product; or

             1.8.5  The complete liquidation or dissolution of GB.

                                       3
<PAGE>

     1.9   "Coated Component" means low polarization electrode
           coatings, including where the context requires all such Products
           manufactured by GB and sold to SORIN/ELA under this Agreement.

     1.10  "Confidential Information" means know-how, trade secrets, and
           unpublished information disclosed (whether before or during the term
           of this Agreement) by one of the parties (the "disclosing party") to
           the other party (the "receiving party"), and which is marked as
           proprietary or confidential as provided below.

           All Confidential Information disclosed by one party to the other
           under this Agreement shall be in writing and bear a legend
           "Proprietary," "Confidential" or words of similar import or, if
           disclosed in any manner other than writing, shall be followed by
           confirmation that such information is confidential by the disclosing
           party within*. The following information communicated to GB by
           SORIN/ELA shall be considered Confidential Information of SORIN/ELA
           for purposes of, and subject to, Article 8 and the other provisions
           of this Agreement whether or not marked "Proprietary" or
           "Confidential":

                  1.10.1   Specifications;
                  1.10.2   Information regarding circuitry design or mechanical
                           design;
                  1.10.3   Information regarding product or component
                           qualification or verification; and

     The following information communicated to SORIN/ELA by GB shall be
     considered Confidential Information of GB for purposes of, and subject to,
     Article 8 and the other provisions of this Agreement whether or not marked
     "Proprietary" or "Confidential":

                  1.10.4   information regarding delivery or production
                           schedules;
                  1.10.5   information regarding GB delivery and production
                           schedules or production capacity;
                  1.10.6   information regarding GB product or component
                           qualification or verification;
                  1.10.7   information related to GB manufacturing processes;
                  1.10.8   information related to Product technology including
                           GB designs and materials used for components and
                           assemblies; and
                  1.10.9   information related to Product pricing.

     1.11  "Contract Year" means each calendar year during the Term, provided
           that for clarification the initial Contract Year shall mean 2006.

     1.12  "Effective Date" means the date this Agreement is signed by the
           parties hereto.

     1.13  "Feedthrough" means a subassembly consisting of: (a) an outer
           electrically conductive member (usually referred to as a flange or
           ferrule), (b) an inner electrically conductive member or members
           (usually represented as a metallic wire or pin, or multiple wires or
           pins), and (c) a nonconductive material fused or brazed between the
           inner and outer members (usually a glass or ceramic material) such
           that

                                       4
<PAGE>

           they are electrically insulated and hermetically sealed; including
           where the context requires all such Products manufactured by Seller
           and sold to Buyer under this Agreement.

     1.14  "Filtered Feedthrough" means an assembly consisting of:
           (a) Feedthrough and (b) feedthrough type capacitor composed of ground
           electrodes interleaved with conductive active electrodes, one for
           each active feedthrough pin; including where the context requires all
           such Products manufactured by Seller and sold to Buyer under this
           Agreement.

     1.15  "Force Majeure" is defined in Article 9.

     1.16  "Intellectual Property" means U.S. and foreign Patent Rights,
           trademarks, service marks and registrations thereof and applications
           therefore, copyrights and copyright registrations and applications,
           mask works and registrations thereof, Know-How, trade secrets,
           Inventions, discoveries, ideas, technology, data, information,
           processes, drawings, designs, licenses, computer programs and
           software, and technical information including but not limited to
           information embodied in material specifications, processing
           instructions, equipment specifications, product specifications,
           confidential data, electronic files, research notebooks, invention
           disclosures, research and development reports and the like related
           thereto, all amendments, modifications, and improvements to any of
           the foregoing.

     1.17  "Miscellaneous Piece Parts" means machined and molded components used
           in the manufacturing of implantable medical devices, including, but
           not limited to,* and such items including where the context requires
           all such Products manufactured by GB and sold to SORIN/ELA under this
           Agreement.

     1.18  "Product" means Assembled Headers, Batteries, Capacitors, Cases,
           Coated Components, Feedthroughs, Filtered Feedthroughs, and
           miscellaneous piece parts, in each case identified on Exhibits B, C,
           D, E and F, as modified from time to time by mutual written
           agreement.

     1.19  "Qualification" means Product performance testing conducted according
           to an approved and controlled protocol to ensure that the Products
           meet Specifications. Products used to perform the qualification must
           be manufactured using validated equipment and processes per GB
           procedures.

     1.20  "SORIN/ELA" means SORIN BIOMEDICA CRM and ELA MEDICAL SAS and their
           Affiliates.

     1.21  "Specifications" means (i) with respect to Products listed on
           Exhibits B, C, D, E and F as of the date hereof, all applicable
           requirements and protocols provided to GB by SORIN/ELA prior to the
           date of this Agreement as provided hereunder, and approved by GB in
           writing, relative to the design, physical characteristics, function,
           performance, manufacture, packaging and quality of such Products, in
           each case as modified by Article 2.2. To the extent not superseded by
           the foregoing, Specifications will also include all specifications
           and protocols applicable to the Products published by GB.

                                       5
<PAGE>

     1.22  "Term" means the period of time this Agreement is in effect as
           provided for in Article 6.1.

     1.23  "GB" means Greatbatch, Inc. and its Affiliates.

2.0  PRODUCT PURCHASE AND SALE.
     -------------------------

     2.1  Manufacture and Supply. GB shall supply Products to SORIN/ELA in the
          quantities ordered by SORIN/ELA from time to time and in accordance
          with the Specifications agreed to by the parties and with the
          schedules for deliveries thereof established pursuant to this
          Agreement

     2.2  Specifications. All Products supplied by GB to SORIN/ELA shall be in
          accordance with the Specifications and supplied after Qualification
          thereof. Any changes to Specifications for Products to be sold under
          this Agreement shall be agreed upon by both parties in writing.

     2.3  Quality Control. GB agrees to follow strict quality control standards
          with respect to the production and transport of Products sold under
          this Agreement and consistent in all material respects with the
          standard of care and science applicable at the time of delivery.
          SORIN/ELA agrees to follow strict quality control standards with
          respect to the storage, preservation and use of Products purchased
          under this Agreement and consistent in all material respects with such
          guidelines as GB may from time to time deliver to SORIN/ELA.

     2.4  GB / SORIN/ELA Supply Agreement and Extension. SORIN/ELA and GB desire
          to terminate (i) the original Purchase Agreement between GBL and Ela
          Medical S.A. signed on or about November 17, 2000 by ELA Medical; and
          (ii) the Supply Agreement Pricing Amendment, signed on or about
          November 16, 2001 (the "Current Supply Agreement") by Sorin and Ela,
          and the Supply Agreement Extension executed on or about 19 January
          2006, which is superseded by this Agreement; provided, however, that
          any financial and other obligations owing by one party to the other,
          and any such obligations which, by their terms survive termination of
          these Agreements, shall not be terminated by virtue of this Article
          2.4.

     2.5  Standard Forms Not Applicable. The general terms and conditions of
          sale for Products sold by GB to SORIN/ELA hereunder are exclusively
          set forth in this Agreement. The parties expressly agree that none of
          the terms and conditions of any written or electronic standard or
          other preprinted forms used by either GB or the SORIN/ELA in
          effectuating the purchase and sale transactions contemplated by this
          Agreement (including, but not limited to, purchase orders,
          acknowledgements and acceptance forms, invoices, labels and shipping
          documents) which are inconsistent with, or in addition to, those
          contained in this Agreement shall have any force or effect.

     2.6  *:  SORIN/ELA will provide GB the* SORIN/ELA with*.

3.0  PRICE.
     -----

     3.1  Pricing.  The initial prices for Products are set forth on Exhibits B,
          C, D, E and F.

                                       6
<PAGE>

     3.2  *

     3.3  Payment Terms. Payment terms are net* from date of invoice and terms
          are* or the location of such other* facility that manufactures the
          Product ("FCA" per INCOTERMS 2000). Remittances are to be made per the
          following:

                  Please direct all Wire Transfer Payments to:
                   -------------------------------------------
                                 Account Name: *
                                Account Number: *
                                     ABA: *
                                  Bank Name: *
                            Swift Code (if needed): *

     3.4  Price Adjustments for Significant Cost Impact. The price for any
          product may be adjusted up or down during the term of this agreement,
          by mutual consent, if there is significant impact to the final cost of
          the Product:
                  3.4.1    In the case of * the price of any Product is subject
                           to *modification from time to time due to *. The
                           reference price of * will be based upon the *
                  3.4.1.1  *shall be executed (reflecting revised SORIN/ELA
                           pricing) on an agreed upon volume and timing basis.
                           Specifically, GB agrees to *with SORIN/ELA's formal
                           agreement on pricing, volume, and delivery
                           requirements.
                  3.4.1.2  The cost of * used as the basis to establish pricing
                           in Exhibit C of this Agreement was *.
                  3.4.2    In the case of *, the price of any Product is subject
                           *modification from time to time due to *. The
                           reference price of * will be based upon the * as
                           reported by the * The cost of * used as the basis to
                           establish pricing in Exhibits E, F and G of this
                           Agreement was *
                  3.4.3    In the case of *, the price of any Product is subject
                           to *modification from time to time due to *. The
                           reference price of *will be based upon the "*" as
                           reported by the *. The cost of *used as the basis to
                           establish pricing in Exhibits E, F and G of this
                           Agreement was *.
                  3.4.4    If GB determines that a price *under this Article is
                           required or permissible, GB shall deliver written
                           notice to SORIN/ELA setting forth the basis for such
                           determination. The new price(s) shall be in effect *
                           of GB's notification to SORIN/ELA.

     3.5  Price Adjustments for *.

                  3.5.1    The price for a Product from time to time as set
                           forth on Exhibits B, C, D, E and F is subject to *
                           modification in the event that a redesign of a
                           Product results in *of the Product.
                  3.5.2    If SORIN/ELA determines that it is necessary or
                           desirable to make a change to the applicable
                           Specifications for any Product, then SORIN/ELA will
                           so notify GB in writing. GB will respond to SORIN/ELA
                           in writing as soon as practicable, but in no event
                           later than *, after the date of any such notice,

                                       7
<PAGE>

                           specifying (i) GB's suggestions, if any, for
                           modifying SORIN/ELA'S Specifications change; (ii) the
                           lead time necessary to implement such change; and
                           (iii) the amount and nature of any *, if any,
                           estimated to result from implementing such change.
                           The parties agree to negotiate in good faith after
                           delivery of such notice with respect to an adjustment
                           to the Specifications *. If the Specification changes
                           requested by SORIN/ELA for a Product are agreed to by
                           GB, SORIN/ELA will be responsible for all finished
                           product, WIP raw components, and any non-cancelable
                           purchase orders outstanding with GB's suppliers
                           *requirements for the Product (as listed in Exhibit
                           G), that do not meet the revised Specifications.

     3.6  Non-Recurring Charges. GB and SORIN/ELA agree to *, for Products that
          are developed by GB for SORIN/ELA, including, but not limited to,
          Products included in this Agreement in Exhibits B, C, D, E and F.

     3.7  U.S. Funds. All amounts referenced in or to be paid under this
          Agreement shall be in U.S. funds.

     3.8  *. During the Term of the Agreement, GB and SORIN/ELA agree to explore
          the opportunity for GB to *.

4.0  ORDERS AND FORECASTS.
     --------------------

     4.1  Firm Purchase Orders for Products and Forecasts.

                  4.1.1    By *of each Contract Year, SORIN/ELA shall provide GB
                           with a non-binding *forecast indicating SORIN/ELA'S
                           forecasted purchases of Products from GB for the next
                           Contract Year. The forecast for the months remaining
                           in 2006 shall be provided within *of the effective
                           date of this Agreement. The forecast shall be used
                           for purposes of facilitating each party's planning
                           and in order to meet the lead times required by
                           certain of GB's suppliers. Such forecasts are not
                           legally binding in any manner and may be revised from
                           time to time by SORIN/ELA, as it deems appropriate,
                           by providing notice to GB.

                  4.1.2    By the *day of every month, SORIN/ELA will submit to
                           GB in writing the following information:

                  4.1.2.1  A rolling *forecast of anticipated needs. Such
                           forecast shall not be binding on SORIN/ELA or GB.
                           Only a firm purchase order that is accepted by GB
                           shall create a binding commitment.

                  4.1.2.2  A firm purchase order for each of the immediately
                           following *

                  4.1.3    Upon completion of any Specifications for and
                           Qualification of new models of Products by the
                           parties, SORIN/ELA agrees to provide GB with an

                                       8
<PAGE>

                           initial *forecast indicating SORIN/ELA'S forecast
                           purchases of Products from GB during that period *

                  4.1.4    All Firm Purchase Orders shall set forth at a
                           minimum: (i) an identification of Products ordered,
                           (ii) quantities ordered, (iii) proposed delivery
                           dates, and (iv) shipping instructions.

                  4.1.5    Items

                  4.1.5.1  GB shall cause Products to be delivered to
                           SORIN/ELA'S facilities per SORIN/ELA'S delivery
                           instructions;

                  4.1.5.2  unless SORIN/ELA gives GB written instructions as to
                           the method of shipment and carrier, GB shall select
                           the methods of shipment and the carrier for the
                           respective purchase order, and GB shall prepay
                           transportation and similar charges upon shipment
                           (which payments shall be added to the invoice); and

                  4.1.5.3  title to all Products conforming to SORIN/ELA'S
                           purchase order shall pass, free and clear of all
                           encumbrances, at the FCA shipping point, which shall
                           be *, and SORIN/ELA assumes and agrees to bear all
                           risk of damage or loss to the goods after delivery by
                           GB to the carrier at the FCA shipping point, and
                           SORIN/ELA hereby releases GB from any and all claims
                           and liability with respect to any such in-transit
                           damages or losses to the goods. SORIN/ELA shall also
                           be responsible for securing insurance coverage to
                           cover shipments and deliveries thereunder.

     4.2  Modification of Orders. No Firm Purchase Order by SORIN/ELA
          shall be modified or canceled except upon the written mutual
          agreement of the parties. Mutually agreed change orders
          shall be subject to all provisions of this Agreement,
          whether or not the change order so states. Notwithstanding
          the foregoing, *.

     4.3  Order Limitations. In the event that:

                  4.3.1    Firm Purchase Orders placed by SORIN/ELA for any
                           Product(s) for delivery within any *for such Product
                           ordered by SORIN/ELA under the most recent prior
                           period of *of SORIN/ELA Firm Purchase Orders by more
                           than *, and
                  4.3.2    The Firm Purchase Orders *then GB shall not be
                           obligated to supply any such excess above such *,
                           however, GB shall use all reasonable commercial
                           efforts to supply amounts requested for delivery
                           which are in excess of such overage, it being
                           understood that in the supply of any such excess
                           beyond the permitted overage GB may take into account
                           delivery commitments to other customers.
                  4.3.3    Should such order increases by SORIN/ELA result in *
                           due to the need by *the right to make *for the
                           product volume that * to account for *, not
                           withstanding the terms of Articles 3.3 and 3.4.

                                       9
<PAGE>

     4.4  Failure to Ship. Subject to Article 6.3 of this Agreement, if GB fails
          for any reason, other than Force Majeure or breach of this Agreement
          by SORIN/ELA, to ship to SORIN/ELA *of Products meeting SORIN/ELA'S *
          (as contemplated by Articles 4.1, 4.2 and 4.3), GB agrees to provide
          SORIN/ELA with *.

     4.5  Standard Lead Time. Standard lead-time for the Products is listed in
          Exhibit G. GB will notify SORIN/ELA, in writing, of any changes to
          these standard lead times. In the event that SORIN/ELA cancels a firm
          purchase order inside agreed upon lead-time, SORIN/ELA *. SORIN/ELA
          will also be responsible for *. In the event that SORIN/ELA cancels a
          firm purchase order outside of agreed upon lead-time, SORIN/ELA and GB
          *.

     4.6  Testing and Inspection.

             4.6.1   GB shall perform testing to ensure that Products delivered
                     to SORIN/ELA meet all applicable Specifications. SORIN/ELA
                     inspection of incoming Products will rely upon GB testing
                     and may consist of an examination of GB's testing
                     documentation as well as independent testing by SORIN/ELA.

             4.6.2   SORIN/ELA shall conduct any incoming inspection tests not
                     later than * from the date of * Products. Products not
                     rejected by SORIN/ELA by written notice to GB within such
                     period shall be deemed accepted.

             4.6.2.1 In the event of any shortage, damage or discrepancy in or
                     to a shipment of Products or in the event any Products fail
                     to comply with the then current specifications for
                     Products, SORIN/ELA shall promptly report the same to GB
                     and furnish such written evidence or other documentation as
                     GB reasonably may deem appropriate.

             4.6.2.2 If evidence indicates that such shortage, damage or
                     discrepancy or nonconformity with specifications existed at
                     the time of delivery of the Products at the FCA shipping
                     point, SORIN/ELA may return the Products to GB at GB's
                     expense, and at SORIN/ELA'S request, GB shall promptly
                     deliver substitute Products to SORIN/ELA in accordance with
                     delivery procedures set forth herein

             4.6.2.3 Prior to returning any Product to GB, SORIN/ELA will first
                     contact its GB customer service representative and obtain a
                     return material authorization (RMA) number. SORIN/ELA will
                     only return the items and quantities approved through the
                     RMA.

             4.6.3   If GB determines that it is necessary or desirable to make
                     any change affecting the form, fit, function, or
                     performance of any Product, GB will immediately notify
                     SORIN/ELA in writing. GB shall not implement any such
                     change without SORIN/ELA'S prior consent.

                                       10
<PAGE>

5.0  WARRANTY AND LIMITATION OF LIABILITY.
     ------------------------------------

     5.1  Warranty. GB warrants to SORIN/ELA that Products sold by GB to
          SORIN/ELA under this Agreement shall be in conformance with applicable
          Specifications and shall be free from defects in material and
          workmanship at the time of delivery of said Products.

     5.2  Limited Warranty. THE WARRANTIES SET FORTH ABOVE ARE IN LIEU OF ALL
          OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED AND
          EXCLUDED BY GB, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF
          MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE OR USE OR OF
          NONINFRINGEMENT.

     5.3  Remedies for Breach of Warranty. In the event that any Product
          manufactured or sold by GB to SORIN/ELA under this Agreement fails to
          comply with the limited warranty provided for in this Article 5 and
          SORIN/ELA delivers notice of such noncompliance to GB, within * of the
          delivery of such Product to SORIN/ELA, GB will, upon substantiation
          that the Product has been stored, preserved and used in accordance
          with Article 2.3, correct such failure by suitable repair or
          replacement at its own expense. GB agrees that it will promptly inform
          SORIN/ELA in writing of any actual or potential problems of which GB
          becomes aware relating to the performance of any Product design
          manufactured for SORIN/ELA relative to the specifications for such
          design.

     5.4  LIMITATION OF LIABILITY. THE REPAIR OR REPLACEMENT OF ANY EFFECTIVE
          PRODUCT OR ANY PRODUCT WHICH DOES NOT CONFORM WITH APPLICABLE
          SPECIFICATIONS AS PROVIDED FOR HEREIN, IN THE MANNER PROVIDED ABOVE,
          SHALL CONSTITUTE THE FULL EXTENT OF GB'S LIABILITY TO SORIN/ELA WITH
          RESPECT TO PRODUCTS SOLD HEREUNDER. IN NO EVENT SHALL GB BE LIABLE
          UNDER THIS AGREEMENT FOR INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES,
          INCLUDING, BUT NOT LIMITED TO, LOSS OF SALES, PROFITS OR REVENUES OR
          COSTS OF ANY PARTIAL OR TOTAL RECALL OF DEVICES IN WHICH PRODUCTS MAY
          HAVE BEEN INCORPORATED, AND IN NO EVENT SHALL GB BE LIABLE IN AN
          AMOUNT IN EXCESS OF ITS PRODUCT LIABILITY INSURANCE AS PROVIDED FOR
          UNDER ARTICLE 5.6.1. THE PROVISIONS OF THIS ARTICLE 5 SHALL SURVIVE
          THE EXPIRATION OR TERMINATION OF THIS AGREEMENT.

     5.5  Quality Management

             5.5.1   Quality Management System. GB has established and maintains
                     a certified Quality Management System in accordance with
                     ISO 9001-2000 and other relevant quality management
                     standards and legal provisions applicable to its business.
                     GB represents and warrants that the actual production of
                     the Product takes place under such Quality Management
                     System. GB and SORIN/ELA acknowledge and agree that GB is
                     not subject to *or *.

                                       11
<PAGE>

             5.5.2   Audits and Inspections. SORIN/ELA shall have reasonable
                     access to the portion of GB's premises in which Products
                     are manufactured for SORIN/ELA, and its relevant
                     documentation, during regular business hours in order to
                     verify that the production and inspection of the Products
                     occur and occurred under application of all relevant
                     provisions of GB's certified Quality Management System and
                     in compliance with the Product Specification. GB will also
                     fully support and permit any inspection or audit by any
                     conformity assessment body, which is legally entitled to
                     inspect or audit SORIN/ELA, as the legal manufacturer of a
                     medical device (which includes a Product), and GB, as the
                     manufacturer of such Product.

             5.5.3   Compliance Inspection. GB shall inspect and test Products
                     prior to delivery to SORIN/ELA to ensure compliance with
                     the Product Specification.

             5.5.4   Traceability. In accordance with the relevant quality
                     standards and internal GB procedures, traceability of
                     critical or major components, processes, manufacturing and
                     release inspection results will be maintained by GB, per GB
                     documentation retention standards, to the individual
                     Product identified by serial or lot number.

             5.5.5   Compliance Notification. It is SORIN/ELA'S sole
                     responsibility to file Medical Device Reports or Vigilance
                     Reports to any legal authority for the medical devices
                     which contain a Product in order to comply with the
                     applicable laws and regulations.

             5.5.6   Survival.  The provisions of this Article 5.5 shall survive
                     the termination of the Agreement.

     5.6  Product Liability Insurance.

             5.6.1   GB shall procure and maintain product liability insurance
                     in such amounts as ordinary good business practice for its
                     type of business would make advisable and shall provide
                     SORIN/ELA with evidence of this coverage; provided,
                     however, that in no case shall the limits of such coverage
                     be less than the following (but subject to any deductible
                     or self-insured retention (SIR) which shall not exceed *):

             5.6.1.1 Bodily Injury:
             o*             Each Occurrence
             o*             General Aggregate

                                       12
<PAGE>

             5.6.1.2 Property Damage:
             o*             Each Occurrence
             o*             General Aggregate

             GB shall provide SORIN/ELA with an insurance certificate on or
             before January 30th of each year concerning the year started
             specifying the amounts stated in this article including the SIR.

                     5.6.2  SORIN/ELA shall procure and maintain product
                            liability insurance in such amounts as ordinary good
                            business practice for its type of business would
                            make advisable and shall provide GB with evidence of
                            this coverage; provided, however, that in no case
                            shall the limits of such coverage be less than the
                            following (but subject to any deductible or
                            self-insured retention (SIR) which shall not
                            exceed *):

             5.6.2.1 Bodily Injury:
             o*             Each Occurrence
             o*             General Aggregate

             5.6.2.2 Property Damage:
             o*             Each Occurrence
             o*             General Aggregate

             SORIN/ELA shall provide GB with an insurance certificate on or
             before January 30th of each year concerning the year started
             specifying the amounts stated in this article including the SIR.

     5.7  Indemnification.

             5.7.1   SORIN/ELA hereby agrees to indemnify, defend and hold GB,
                     its Affiliates and each of their officers, directors and
                     employees harmless from any damage, costs or liabilities,
                     including, without limitation, any reasonable costs or
                     legal fees thereby incurred by GB and payable to third
                     parties (collectively, "damages") arising out of any claim
                     to the extent that such claim arises from or results out of
                     the marketing, distribution or sale of medical devices by
                     SORIN/ELA which contain a Product, including, without
                     limitation:

             5.7.1.1 personal injury or death resulting from the use of a
                     medical device containing a Product;

             5.7.1.2 alleged defects of the medical devices containing a
                     Product; and

                                       13
<PAGE>

             5.7.1.3 any breach by SORIN/ELA of its covenants contained in
                     this Agreement.

          unless the damage is solely caused by GB's negligence, wilful
          misconduct or breach of this AGREEMENT.

             5.7.2   Indemnification Procedure. GB shall give SORIN/ELA written
                     notice of any claim *of its first knowledge thereof.

6.0  CONTRACT TERM
     -------------

     6.1  This Agreement shall commence on the Effective Date and have an
          initial term ending on December 31, 2010 ("Initial Term"). Pricing set
          forth in Exhibits B, C, D, E and F is in effect as of the Effective
          Date. This Agreement may be extended for renewal terms, the length of
          which to be set by mutual written agreement. In that regard, unless
          either party gives notice of termination not less than * prior to the
          expiration of the Initial Term or any such renewal term, the parties
          will meet prior to each such expiration to negotiate price or other
          changes to this Agreement. Unless the parties mutually agree in
          writing, however, this Agreement shall not be extended and shall
          expire by its terms at the end of the Initial Term or any such renewal
          term.

     6.2  Termination. Notwithstanding the provisions of Article 6.1 above, this
          Agreement may be terminated in accordance with the following
          provisions:

             6.2.1   A party may terminate this Agreement by giving notice in
                     writing to the other party in the event the other party is
                     in breach of any material representation, warranty or
                     covenant of this Agreement and shall have failed to cure
                     such breach within * of receipt of written notice thereof
                     from the first party;

             6.2.2   A party may terminate this Agreement at any time by giving
                     notice in writing to the other party, which notice shall be
                     effective upon dispatch, should the other party file a
                     petition of any type as to its bankruptcy, be declared
                     bankrupt, become insolvent, make an assignment for the
                     benefit of creditors, go into liquidation or receivership;
                     or

             6.2.3   A party may terminate this Agreement by giving notice in
                     writing to the other party should an event of Force Majeure
                     continue for more than *as provided in Article 9.1 below.

     6.3  Rights and Obligations on Termination. Termination of this Agreement
          shall not release either party from the obligation to make payment of
          all amounts previously due and payable, or which become due and
          payable due to termination of this Agreement. In addition,

             6.3.1   In the event of early termination by SORIN/ELA, GB will *
                     all Products up to the date the termination letter is
                     received by GB.

                                       14
<PAGE>

                     SORIN/ELA will * to SORIN/ELA Product unless such
                     termination was pursuant to Article 6.2.1 and such
                     termination was due to a fundamental failure of GB to
                     perform its obligation under this Agreement after notice
                     thereof.

             6.3.2   Upon expiration or termination of this Agreement for any
                     reason whatsoever or if SORIN/ELA changes the model mix of,
                     or discontinues, any Products which it requires, resulting
                     in the cancellation of firm purchase orders inside the
                     standard lead times, SORIN/ELA*. SORIN/ELA will *. In the
                     event that SORIN/ELA cancels a firm purchase order outside
                     of agreed upon lead-time, SORIN/ELA and GB *.

7.0  BUSINESS EXIT
     -------------

     7.1  GB must give SORIN/ELA *of any intent to discontinue supply of any
          Product to SORIN/ELA ("Article 7.0 Notice"), but GB *. If GB so
          informs SORIN/ELA of its intent to discontinue, SORIN/ELA shall have
          the right to * as set forth by GB in the Article7.0 Notice, which will
          be fulfilled by GB provided that (i) units of Product covered by
          *shall, for any Product, *the number of units of such Product
          delivered to SORIN/ELA in the *the date of this Article 7.0 Notice;
          and (ii) GB may deliver Product *.

8.0  CONFIDENTIALITY.
     ---------------

     8.1  Confidential Information. The receiving party agrees to maintain the
          confidentiality of the Confidential Information of the disclosing
          party and agrees not to disclose or use (except as permitted or
          required for performance by the receiving party of its rights or
          duties hereunder) any Confidential Information of the disclosing
          party; provided, however, that a party shall not be so restricted from
          using or disclosing any information (that otherwise is covered under
          the Confidential Information) that:

             8.1.1   was already in the possession of the receiving party prior
                     to its receipt from the disclosing party (provided that the
                     receiving party is able to provide the disclosing party
                     with reasonable documentary proof thereof);

             8.1.2   is or becomes part of the public domain by reason of acts
                     not attributable to the receiving party;

             8.1.3   is or becomes available to the receiving party from a
                     source other than the disclosing party which source, to the
                     best of the receiving party's knowledge, has rightfully
                     obtained such information and has no obligation of
                     nondisclosure or confidentiality to the disclosing party
                     with respect thereto;

                                       15
<PAGE>

             8.1.4   is made available by the disclosing party to a third party
                     unaffiliated with the disclosing party on an unrestricted
                     basis;

             8.1.5   is independently developed by the receiving part
                     completely without reference to any Confidential
                     Information of the disclosing party, as evidenced by the
                     receiving party's written records; or

             8.1.6   has been or must be publicly disclosed by reason of legal,
                     accounting or regulatory requirements beyond the reasonable
                     control, and despite the reasonable efforts, of the
                     receiving party.

The receiving party further agrees to take appropriate measures to prevent any
such prohibited disclosure by its and its subsidiaries' present and future
employees, officers, agents and consultants.

     8.2  Public Statements. Notwithstanding anything to the contrary contained
          in this Agreement, neither party may initiate or make any public
          announcement or other disclosure concerning the terms and conditions
          or the subject matter of this agreement to any third party without the
          prior written approval of the other party except as may be required by
          law. In those circumstances where either party believes that any such
          disclosure is required by law, it shall (a) notify the other party on
          a timely basis in advance and (b) use its best efforts to seek
          confidential treatment of the material provisions of this agreement,
          to the greatest extent permitted by law.

9.0  FORCE MAJEURE.
     -------------

     9.1  "Force Majeure" shall mean storm, earthquake, embargoes, and acts of
          God, war and/or public enemy that prevents in whole or in material
          part the performance by one of the parties of its obligations
          hereunder.

     9.2  Upon giving notice to the other party, a party affected by an event of
          Force Majeure shall be released without any liability on its part from
          the performance of its obligations under this Agreement, except for
          the obligations under Article 3 hereof and to pay any amounts due and
          owing hereunder, but only to the extent and only for the period that
          its performance of such obligations is prevented by the event of Force
          Majeure.

     9.3  During the period that the performance by one of the parties of its
          obligations under this Agreement has been suspended by reason of an
          event of Force Majeure, the other party may likewise suspend the
          performance of all or part of its obligations hereunder to the extent
          that such suspension is commercially reasonable.

10.0 INTELLECTUAL PROPERTY.
     ---------------------

     10.1 Ownership of Product Technology.

                                       16
<PAGE>

             10.1.1  All Product Technology is the sole property of GB. Nothing
                     in this Agreement shall give SORIN/ELA any license, claim,
                     right, title or interest in GB's Technology.

             10.1.2  Any and all inventions, additions and/or improvements
                     relating to the Products, their use in implantable medical
                     devices or in respect of the Product Technology developed,
                     conceived, or invented solely by GB during the term of this
                     Agreement shall be the sole property of GB.

             10.1.3  Any and all inventions, additions and/or improvements
                     relating to the Products, their use in implantable medical
                     devices or in respect of the Product Technology developed,
                     conceived, or invented solely by SORIN/ELA during the term
                     of this Agreement shall be the sole property of SORIN/ELA.

             10.1.4  Any and all inventions, additions and/or improvements
                     relating to the Products, their use in implantable medical
                     devices or in respect of the Product Technology developed,
                     conceived, or invented jointly by GB and SORIN/ELA during
                     the term of this Agreement shall be *For purposes hereof,
                     the sole standard for establishing whether or not any
                     inventions, additions and/or improvements relating to the
                     Products *will be that, if the all inventions, additions
                     and/or improvements relating to the Products in question *.

             10.1.5  *. However, SORIN/ELA is required to * regarding the
                     Products should SORIN/ELA *.

             10.1.6  *shall be subject to all of the terms and conditions of
                     this Agreement.

11.0 MISCELLANEOUS.
     -------------

     11.1 Governing Law. This Agreement shall be interpreted, construed and
          governed by and in accordance with the laws of the State of New York.
          The parties expressly agree that the United Nations Convention on the
          International Sale of Goods shall not apply to this Agreement on any
          transaction pursuant hereto.

     11.2 Assignment. Either party may assign this agreement to an entity that
          acquires, directly or indirectly, substantially all of the assets or
          merges with it. Except as set forth herein, neither this Agreement nor
          any rights here under, in whole or in part, shall be assignable or
          otherwise transferable by either party without the express written
          consent of the other party. Subject to the above, this Agreement shall
          be binding upon and inure to the benefit of the successors and assigns
          to the parties here to.

                                       17
<PAGE>

     11.3 Integration. This Agreement constitutes the entire agreement of the
          parties with respect to the subject matter hereof and supersedes all
          previous agreements or proposals, oral or written, and all
          negotiations, conversations or discussions heretofore had between the
          parties related to the subject matter of this Agreement, but excluding
          any confidentiality agreements between the parties or their Affiliates
          which shall remain in full force and effect.

     11.4 Survival. All of the representations, warranties, and indemnifications
          made in this Agreement, and all terms and provisions hereof intended
          to be observed and performed by the parties after the termination
          hereof, shall survive such termination and continue thereafter in full
          force and effect, subject to applicable statute of limitations.

     11.5 Amendment; Waiver. This Agreement may not be released, discharged,
          abandoned, changed or modified in any manner, except by an instrument
          in writing signed on behalf of each of the parties to this Agreement
          by their duly authorized representatives. The failure of either party
          to enforce at any time any of the provisions of this Agreement shall
          in no way be construed to be a waiver of any such provision, nor in
          any way to affect the validity of this Agreement or any part of it or
          the right of either party after any such failure to enforce each and
          every such provision. No waiver of any breach of this Agreement shall
          be held to be a waiver of any other or subsequent breach.

     11.6 Counterparts. This Agreement may be executed in one or more
          counterparts, all of which shall be considered one and the same
          agreement, and become a binding agreement when one or more
          counterparts have been signed by each party and delivered to the other
          party.

     11.7 Headings. The titles and headings to Articles herein are inserted for
          the convenience of reference only and are not intended to be a part of
          or to affect the meaning or interpretation of this Agreement. This
          Agreement shall be construed without regard to any presumption or
          other rule requiring construction hereof against the party causing
          this Agreement to be drafted. All references to Articles, Articles and
          Exhibits shall mean Articles and Sections of, and Exhibits to, this
          Agreement.

     11.8 No Third Party Beneficiaries. Nothing in this Agreement, expressed or
          implied, is intended to confer on any person other than the parties to
          this Agreement and their Affiliates, or their respective successors or
          assigns, any rights, remedies, obligations or liabilities under or by
          reason of this Agreement.

                                       18
<PAGE>

     11.9  Notices. Any notice or other communication hereunder must be given in
           writing and either (a) delivered in person, (b) transmitted by telex,
           facsimile or telecopy mechanism, provided that any notice so given is
           also mailed as provided in clause (c), or (c) mailed, postage
           prepaid, receipt requested as follows:

             If to GB:                                 If to SORIN/ELA:
             9645 Wehrle Drive                         13040 Saluggia (VC)
             Clarence, New York 14031                  Via Crescentino, Italy
             Facsimile:       716.759.5664             Facsimile: 39.0161.487874
             Attention:       President                Attention: President
             CC: Legal Department

           or to such other address or to such other person as either party
           shall have last designated by such notice to the other party. Each
           such notice or other communication shall be effective (i) if given by
           telecommunication, when transmitted to the applicable number so
           specified in (or pursuant to) this Article 11.9 and an appropriate
           receipt is received, (ii) if given by mail, three (3) days after such
           communication is deposited in the mails with first class postage
           prepaid, addressed as aforesaid or (iii) if given by any other means,
           when actually received at such address.

     11.10 Severability. If any provision of this Agreement is held invalid by a
           court of competent jurisdiction, the remaining provisions shall
           nonetheless be enforceable according to their terms. Further, if any
           provision is held to be overbroad as written, such provision shall be
           deemed amended to narrow its application to the extent necessary to
           make the provision enforceable according to applicable law and shall
           be enforced as amended.

     11.11 Confidentiality. The parties agree that a violation of the
           confidentiality covenants set forth in Article 8 of the Agreement
           will cause damages to the other party that are significant, material
           and difficult or impossible to adequately measure and the injured
           party will be entitled to seek and obtain injunctive relief
           compelling compliance in terms of this Agreement.

     11.12 Arbitration. Except as set forth in Article 11.11 above, all disputes
           and controversies arising out of or relating to this Agreement or any
           of the other documents to be delivered hereunder, or the performance,
           breach, validity, interpretation or enforcement thereof, will be
           resolved by binding arbitration in accordance with the commercial
           arbitration rules of the American Arbitration Association (the
           "Rules"), and judgement upon the award rendered by the arbitrator may
           be entered in any court having jurisdiction thereof. A party may
           initiate arbitration by sending written notice of its intention to
           arbitrate the other parties and to the AAA office located in * (the
           "Arbitration Notice"). The Arbitration Notice will contain a
           description of the dispute and the remedy sought. The arbitration
           will be conducted at the offices of the AAA in *before three
           independent and impartial arbitrators experienced in legal matters
           related to the medical device industry.

                                       19
<PAGE>

           Each party will be entitled to select one arbitrator, and the two (2)
           individuals so selected will select the third arbitrator. In no event
           may the demand for arbitration be made after the date when
           institutions of a legal or equitable proceeding based on such claim,
           dispute or other matter in question would be barred by New York law.
           The Arbitrators will deliver their decision in writing, together with
           the summary of the reasons for their decision, including citations to
           legal authority to the extent appropriate. The decision of the
           arbitrators will be final and binding on both parties and their
           successors and permitted assignees. The parties intend that this
           agreement to arbitrate be irrevocable. The parties agree that,
           notwithstanding anything to the contrary in this Article 11.12, any
           award made by the arbitrators will be consistent with the terms of
           the Agreement and that any award will be restricted to a remedy that
           would be available to a party under this Agreement.

                                       20
<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed
by their authorized representatives.

SORIN/ELA BIOMEDICA CRM               GREATBATCH, INC.

By:                                        By:
   ---------------------------                 ---------------------------------
Title:                                     Title:
      ------------------------                    ------------------------------
Date:                                       Date:
      ------------------------                    ------------------------------

ELA MEDICAL SAS
By:
   ---------------------------
Title:
      ------------------------
Date:
      ------------------------

                                       21
<PAGE>

                                    EXHIBIT A

                               GENERAL CONDITIONS

  1.0   SORIN/ELA must purchase a Minimum Total Dollar Amount of *of Products
        from GB during the Initial Term of the Agreement. The Minimum Total
        Dollar Volumes targets on an annual basis are listed below (aggregate
        $USD):
                        2006 - *
                        2007 - *
                        2008 - *
                        2009 - *
                        2010 - *

        1.1     SORIN/ELA will make every reasonable effort to achieve the
                Minimum total dollar volume targets, as established above,
                on an annual basis; however, the overall minimum total
                dollar amount for the individual periods listed below shall
                be met:

                        Period #1 - 01 January 2006 through 31 December 2007 - *
                        Period #2 - 01 January 2008 through 31 December 2009 - *
                        Period #3 - 01 January 2010 through 31 December 2010 - *

  2.0   No later than *of any Contract Year, SORIN/ELA and GB will *, and
        remaining orders to *.

  3.0   Should it become apparent that the minimum total dollar volumes for
        the periods identified in this Exhibit A 1.1 will not be met by
        SORIN/ELA, *. Upon the event of such * that may include, but will not
        be limited to *.

  4.0   Audit

        4.1     GB will require that SORIN/ELA *, including the Purchase
                Requirements specified in Exhibits B, C, D, E and F.

        4.2     GB reserves the right to * specified in Exhibits B, C, D, E
                an F. The audit process is outlined in Exhibit H.

                                       22
<PAGE>

                                    EXHIBIT B

                      PRICING FOR BATTERIES AND CAPACITORS

1.0  Batteries

        1.1      Lithium Iodine Low-Rate Battery Pricing, Terms and Conditions,
                 including Purchase Requirements

                 1.1.1 Lithium Iodine Low-Rate Battery Pricing

                       --------------------------------
                              Li Iodine Batteries
                       --------------------------------

                       --------------------------------
                             Year         Unit Price
                       ================================

                             2006          *
                             2007          *
                             2008          *
                             2009          *
                             2010          *

                       ================================

                 1.1.2 Purchase Requirements: * of SORIN/ELA'S bradycardia
                       device battery demand to be purchased from GB
                 1.1.3 Pricing for *of *and *of Li Iodine batteries that are *
                 1.1.4 Price premiums to be applied based upon *

        1.2      Lithium Silver Vanadium Oxide High-Rate Battery Pricing, Terms
                 and Conditions, including Purchase Requirements

                 1.2.1 Lithium Silver Vanadium Oxide High-Rate Battery Pricing

                                       23
<PAGE>

                       --------------------------------
                                 SVO Batteries
                       --------------------------------

                       --------------------------------
                           Year            Unit Price
                       ================================

                           2006                *
                           2007                *
                           2008                *
                           2009                *
                           2010                *

                       --------------------------------

                 1.2.2 Purchase Requirements: * of SORIN/ELA'S tachycardia
                       device battery demand to be purchased from GB
                 1.2.3 Pricing for *and *of Lithium Silver Vanadium Oxide
                       High-Rate Batteries that *
                 1.2.4 Price premiums to be applied based upon *

        1.3      QHR Silver Vanadium Oxide/Carbon Monofluoride High Rate Battery
                 Pricing, Terms and Conditions, including Purchase Requirements

                 1.3.1 QHR Silver Vanadium Oxide/Carbon Monofluoride High Rate
                       Battery Pricing

                       --------------------------------
                               QHR Batteries
                       --------------------------------

                       --------------------------------
                           Year            Unit Price
                       ================================

                           2006                *
                           2007                *
                           2008                *
                           2009                *
                           2010                *

                       --------------------------------

                 1.3.2 Purchase Requirements: * of SORIN/ELA'S tachycardia
                       device battery demand to be purchased from GB
                 1.3.3 Pricing for QHR Silver Vanadium Oxide/Carbon Monofluoride
                       High Rate Batteries of *Cathode plate construction that
                       are *
                 1.3.4 Price premiums to be applied based upon *

                                       24
<PAGE>

        2.0      Capacitor Pricing, Terms and Conditions, including Purchase
                 Requirements

                 2.1   Wet Tantalum Capacitor Pricing:

                       --------------------------------
                                 Capacitors
                       --------------------------------

                       --------------------------------
                           Year            Unit Price
                       ================================

                           2006                *
                           2007                *
                           2008                *
                           2009                *
                           2010                *

                       ================================

                 2.2   Purchase Requirements: * of SORIN/ELA'S tachycardia
                       device capacitor demand to be purchased from GB for
                       SORIN/ELA device development platforms currently referred
                       to as *, as well as *

                 2.3   Pricing for *of *

                 2.4   Price Premiums to be applied based upon *

                                       25
<PAGE>

                                    EXHIBIT C

               PRICING FOR FEEDTHROUGHS AND FILTERED FEEDTHROUGHS

        1.0      Feedthrough Pricing, Terms and Conditions, including Purchase
                 Requirements

                 1.1   Feedthrough Pricing

--------------------------------------------------------------------------------
                                  Feedthroughs
--------------------------------------------------------------------------------

                                                   Unit Price
--------------------------------------------------------------------------------

Drawing                 GB Item     2006     2007     2008     2009      2010
================================================================================
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
================================================================================

                 1.2   Purchase Requirements: * of SORIN/ELA'S Feedthrough
                       demand to be purchased from GB

                 1.3   Feedthrough pricing applies to the *of the */ items
                       listed in the table above.

                 1.4   Price premiums to be applied for *and/or *

                                       26
<PAGE>

        2.0      Filtered Feedthrough Pricing, Terms and Conditions, including
                 Purchase Requirements

--------------------------------------------------------------------------------
                             Filtered Feedthroughs
--------------------------------------------------------------------------------

                                                   Unit Price
--------------------------------------------------------------------------------
Drawing                 GB Item     2006     2007     2008     2009      2010
--------------------------------------------------------------------------------
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
================================================================================

                 2.1.1 Filtered Feedthrough Pricing

        2.2      Purchase Requirements:

                 2.2.1 Minimum * of SORIN/ELA'S Filtered Feedthrough demand to
                       be purchased from GB in 2006
                 2.2.2 Minimum * of SORIN/ELA'S Filtered Feedthrough demand to
                       be purchased from GB in 2007
                 2.2.3 *of SORIN/ELA'S Filtered Feedthrough demand to be
                       purchased from GB in 2008 and through termination of this
                       Agreement

        2.3      Filtered Feedthrough pricing applies to the *of the *listed
                 in the table above with the exception of SORIN/ELA drawings
                 *. Pricing for SORIN/ELA drawings *assumes that these
                 Filtered Feedthroughs will be redesigned and qualified by
                 SORIN/ELA

        2.4      Price premiums to be applied for *and/or *

                                       27
<PAGE>

                                    EXHIBIT D

                          PRICING FOR ASSEMBLED HEADERS

1.0     Assembled Header Pricing, Terms and Conditions, including Purchase
        Requirements

                   PRICING PENDING SPECIFICATION CONCURRENCE.

2.0     Purchase Requirements:  Minimum * of SORIN/ELA'S molded Assembled Header
        demand to be purchased from GB in 2007 and through termination of this
        Agreement
3.0     GB and SORIN/ELA mutually agree to *for the new Assembled Headers to be
        included in this Agreement
4.0     GB reserves the right to *for new models and modifications to existing
        models.
5.0     Price premiums to be applied for *and/or *

                                       28
<PAGE>

                                    EXHIBIT E

                                PRICING FOR CASES

1.0     Case Pricing, Terms and Conditions, including Purchase Requirements

--------------------------------------------------------------------------------
                                      Cases
--------------------------------------------------------------------------------

                                                   Unit Price
--------------------------------------------------------------------------------
Drawing                 GB Item     2006     2007     2008     2009      2010
--------------------------------------------------------------------------------

 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *

--------------------------------------------------------------------------------

2.0     GB and SORIN/ELA mutually agree to *for the new Cases included in this
        Agreement
3.0     Case pricing applies only to the *of the */ items listed in the
        table above
4.0     Price premiums apply for *and/*
5.0     Should GB and SORIN/ELA agree to implement *that allow GB to *, the
        following price table *will apply.

                 5.1.1 *will be substantially equivalent to the items as shown
                       in Exhibit I of this Agreement

--------------------------------------------------------------------------------
               CASE PRICING - SPECIFICATION CHANGE PER EXHIBIT I
--------------------------------------------------------------------------------

                                                        Unit Price
                       ---------------------------------------------------------
Drawing                 GB Item     2006     2007     2008     2009      2010
                       =========================================================
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
--------------------------------------------------------------------------------

                                       29
<PAGE>

                                    EXHIBIT F

                      PRICING FOR MISCELLANEOUS PIECE PARTS

1.0     *

        1.1     * Pricing, Terms and Conditions, including Purchase Requirements

--------------------------------------------------------------------------------
                                        *
--------------------------------------------------------------------------------

                                    --------------------------------------------

                                                   Unit Price
--------------------------------------------------------------------------------

Drawing                 GB Item     2006     2007     2008     2009      2010
================================================================================
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
 *                         *          *        *        *        *         *
================================================================================

        1.2     *pricing applies only to the *of the */ items listed in the
                table above
        1.3     Price premiums apply for *and/or *

2.0     Coated Components:  SORIN/ELA agrees to *Coated Components.  GB will *
        once SORIN/ELA'S * by GB.

3.0     Miscellaneous Piece Part Pricing, Terms and Conditions, including
        Purchase Requirements

        3.1     Miscellaneous Piece Part pricing applies only to the *of the */
                items listed in the Pricing Table above
        3.2     Price premiums apply for *and/or *

--------------------------------------------------------------------------------
                           Other Machined Components
--------------------------------------------------------------------------------

                                ------------------------------------------------
                                                   Unit Price
--------------------------------------------------------------------------------

Drawing       GB Item      Type     2006     2007     2008     2009      2010
--------------------------------------------------------------------------------
 *               *           *        *        *        *        *         *
 *               *           *        *        *        *        *         *
 *               *           *        *        *        *        *         *
 *               *           *        *        *        *        *         *
 *               *           *        *        *        *        *         *
================================================================================

                                    EXHIBIT G

                               STANDARD LEAD TIME

Standard Lead Time: The standard lead time for production quantities of fully
qualified Products is *. GB will use *to meet SORIN/ELA'S delivery requirements.
GB will notify SORIN/ELA, in writing, of any changes to these standard lead
times.

                                       30
<PAGE>

                                    EXHIBIT H

                                  AUDIT PROCESS

Audit Process: GB reserves the right to audit SORIN/ELA'S records to validate
SORIN/ELA'S compliance with the terms and conditions of this Agreement,
including the Purchase Requirements specified in Exhibits B, C, D, E and F. The
audit process is outlined below:

        1.0     GB, upon notice to SORIN/ELA, will request that an independent
                CPA firm will audit SORIN/ELA'S information relative to
                volumes. The CPA firm will be one of the Big Four CPA firms
                that is not the external auditor of either GB or SORIN/ELA.
        2.0     *, unless a discrepancy of greater than * exists between
                SORIN/ELA'S claimed volumes versus the volumes discovered
                through the audit process. In this case, *.
        3.0     In the event that GB and SORIN/ELA can not agree regarding the
                results of the audit, another independent CPA firm will be
                requested to audit SORIN/ELA'S information relative to volumes.

                                       31
<PAGE>

                                    EXHIBIT I

                      ENCLOSURE VISUAL INSPECTION CRITERIA

                                        *

                                       32Exhibit 10.1

     

     

    Exhibit
      10.1

     

    LICENSE
      AGREEMENT

     

    DATED
      AUGUST 19, 1991

     

    BY
      AND
      AMONG

     

    THE
      MASSACHUSETTS INSTITUTE OF TECHNOLOGY,

     

    THE
      WHITEHEAD INSTITUTE

     

    AND

     

    ARIAD
      PHARMACEUTICALS, INC.

     

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

    
       

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              WHI
                Vers -1/28/91

            	
              LLN/#4:
                4167ariad.agt

            
	 	Date: August 8,
              1991

    

     

    LICENSE
      AGREEMENT

     

    TABLE
      OF CONTENTS

     

    

      
        	
                PREAMBLE

              	 	 
	 	 	 
	
                ARTICLES:

              	 	 
	 	 	 
	
                ARTICLE
                  I - 

              	
                DEFINITIONS

              	
                3

              
	 	 	 
	
                ARTICLE
                  II - 

              	
                GRANT

              	
                5

              
	 	 	 
	
                ARTICLE
                  III - 

              	
                DUE
                  DILIGENCE 

              	
                7

              
	 	 	 
	
                ARTICLE
                  IV - 

              	
                ROYALTIES

              	
                7

              
	 	 	 
	
                ARTICLE
                  V - 

              	
                REPORTS
                  AND RECORDS 

              	
                9

              
	 	 	 
	
                ARTICLE
                  VI - 

              	
                PATENT
                  PROSECUTION 

              	
                10

              
	 	 	 
	
                ARTICLE
                  VII - 

              	
                INFRINGEMENT

              	
                10

              
	 	 	 
	
                ARTICLE
                  VIII - 

              	
                PRODUCT
                  LIABILITY 

              	
                12

              
	 	 	 
	
                ARTICLE
                  IX - 

              	
                EXPORT
                  CONTROLS 

              	
                12

              
	 	 	 
	
                ARTICLE
                  X - 

              	
                NON-USE
                  OF NAMES 

              	
                12

              
	 	 	 
	
                ARTICLE
                  XI - 

              	
                ASSIGNMENT

              	
                13

              
	 	 	 
	
                ARTICLE
                  XII - 

              	
                ARBITRATION

              	
                13

              
	 	 	 
	
                ARTICLE
                  XIII -

              	
                TERMINATION

              	
                13

              
	 	 	 
	
                ARTICLE
                  XIV - 

              	
                PAYMENTS
                  NOTICES AND OTHER COMMUNICATIONS 

              	
                14

              
	 	 	 
	
                ARTICLE
                  XV - 

              	
                MISCELLANEOUS
                  PROVISIONS 

              	
                15

              
	 	 	 
	
                APPENDIX
                  A 

              	
                 

              	
                17

              
	 	 	 
	
                APPENDIX
                  B 

              	
                 

              	
                19

              
	 	 	 
	
                APPENDIX
                  C 

              	
                 

              	
                20

              
	 	 	 
	
                APPENDIX
                  D 

              	
                 

              	
                24

              
	 	 	 

      

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

    

    This
      Agreement is made and entered into this 19th day of August, 1991, (the Effective
      Date) by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a corporation duly
      organized and existing under the laws of the Commonwealth of Massachusetts
      and
      having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts
      02139, U.S.A. (hereinafter referred to as M.I.T.), and the WHITEHEAD INSTITUTE,
      a corporation organized and existing under the laws of Delaware and having
      its
      principal office at Nine Cambridge Center, Cambridge, Massachusetts 02142,
      U.S.A., (hereinafter referred to as Whitehead) and ARIAD PHARMACEUTICALS, INC.,
      a corporation duly organized under the laws of Delaware and having its principal
      office at 687 Wetherby Lane, Devon, Pennsylvania 19333 (hereinafter referred
      to
      as LICENSEE).

     

    WITNESSETH

     

    WHEREAS,
      M.I.T. and Whitehead are the owners of certain “Patent Rights” (as later defined
      herein) relating to M.I.T. Case No. [***] by [***]; M.I.T. Case No. [***]
      (Whitehead No. [***]) “[***]” by [***]; M.I.T. Case No. [***] (Whitehead No.
      [***]) “[***]” by [***]; M.I.T. Case No. [***] (Whitehead [***]) “[***]” by
      [***] et al.; M.I.T. Case No. [***] (Whitehead No. [***]) “[***]” by [***] and
      has the right to grant licenses under said Patent Rights, subject only to a
      royalty-free, nonexclusive license heretofore granted to the United States
      Government;

     

    WHEREAS,
      Whitehead has authorized M.I.T. to act as its sole and exclusive agent for
      the
      purposes of licensing Whitehead’s rights in the Patent Rights and has authorized
      M.I.T. to enter into this licensing agreement on its own and Whitehead’s
      behalf;

     

    WHEREAS,
      M.I.T. and Whitehead desire to have the Patent Rights utilized in the public
      interest and is willing to grant a license thereunder;

     

    WHEREAS,
      LICENSEE has represented to M.I.T., to induce M.I.T. to enter into this
      Agreement, that LICENSEE is committed to the development and commercialization
      of “Licensed Product(s)” (as later defined herein) and/or the use of the
“Licensed Process(es)” (as later defined herein) and that it shall commit itself
      to a thorough, vigorous and diligent program of exploiting the Patent Rights
      so
      that public utilization shall result therefrom; and

     

    WHEREAS,
      LICENSEE desires to obtain a license under the Patent Rights upon the terms
      and
      conditions hereinafter set forth.

     

    NOW,
      THEREFORE, in consideration of the premises and the mutual covenants contained
      herein the parties hereto agree as follows:

     

    ARTICLE
      I
      - DEFINITIONS

     

    For
      the
      purposes of this Agreement, the following words and phrases shall have the
      following meanings:

     

    1.1          
      “LICENSEE”
      shall include a related company of LICENSEE, the voting stock of which is
      directly or indirectly at least Fifty Percent (50%) owned or controlled by
      LICENSEE, an organization which directly or indirectly controls more than Fifty
      Percent (50%) of the voting 

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    stock
      of
      LICENSEE and an organization, the majority ownership of which is directly or
      indirectly common to the ownership of LICENSEE.

     

    1.2          
      “Patent
      Rights” shall mean all of the following Whitehead and M.I.T. intellectual
      property:

     

    
      	 	
              (a)

            	
              the
                United States and foreign patents and/or patent applications listed
                in
                Appendix A;

            

    

     

    
      	 	
              (b)

            	
              United
                States and foreign patents issued from the applications listed in
                Appendix
                A and from divisionals and continuations of these
                applications;

            

    

     

    
      	 	
              (c)

            	
              claims
                of U.S. and foreign continuation-in-part applications, and of the
                resulting patents, which are directed to subject matter specifically
                described in the U.S. and foreign applications listed in Appendix
                A;

            

    

     

    
      	 	
              (d)

            	
              claims
                of all foreign patent applications, and of the resulting patents,
                which
                are directed to subject matter specifically described in the United
                States
                patents and/or patent applications described in (a), (b), or (c)
                above;

            

    

     

    
      	 	
              (e)

            	
              any
                reissues of United States patents described in (a), (b), (c), or
                (d)
                above. 

            

    

     

    1.3          
      A
      “Licensed Product” shall mean any product or part thereof which:

     

    
      	 	
              (a)

            	
              is
                covered in whole or in part by an issued, unexpired claim or a pending
                claim contained in the Patent Rights in the country in which any
                Licensed
                Product is made, used or sold;

            

    

     

    
      	 	
              (b)

            	
              is
                manufactured by using a process which is covered in whole or in part
                by an
                issued, unexpired claim or a pending claim contained in the Patent
                Rights
                in the country in which any Licensed Process is used or in which
                such
                product or part thereof is used or
                sold;

            

    

     

    
      	 	
              (c)

            	
              contains
                the Tangible Property,

            

    

     

    subject
      to
      the limitations in Paragraph 4.4.

     

    1.4          
      A
      “Licensed Process” shall mean any process which is covered in whole or in part
      by an issued, unexpired claim or a pending claim contained in the Patent Rights
      or which uses the Tangible Property, subject to the limitations in Paragraph
      4.4.

     

    1.5          
      “Net
      Sales” shall mean LICENSEE’s (and its sublicensees’ where appropriate) billings
      for Licensed Products and Licensed Processes produced hereunder less the sum
      of
      the following:

     

    
      	 	
              (a)

            	
              discounts
                allowed in amounts customary in the
                trade;

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    
      	 	
              (b)

            	
              sales,
                tariff duties and/or use taxes directly imposed and with reference
                to
                particular sales;

            

    

     

    
      	 	
              (c)

            	
              outbound
                transportation prepaid or allowed;
                and

            

    

     

    
      	 	
              (d)

            	
              amounts
                allowed or credited on returns.

            

    

     

    No
      deductions shall be made for commissions paid to individuals whether they be
      with independent sales agencies or regularly employed by LICENSEE and on its
      payroll, or for cost of collections. Licensed Products shall be considered
      “sold” when billed out or invoiced.

     

    1.6          
      “Tangible
      Property” shall mean cell lines containing [***] obtained directly or indirectly
      from M.I.T. or Whitehead, and any progeny and derivatives thereof.

     

    ARTICLE
      II
      - GRANT

     

    2.1          
      M.I.T.
      hereby grants to LICENSEE the right and license to make, have made, use, lease
      and sell the Licensed Products, and to practice the Licensed Processes to the
      end of the term for which the Patent Rights are granted unless sooner terminated
      according to the terms hereof.

     

    2.2          
      This
      license shall be subject to the research license and to the option granted
      to
      Centocor to acquire a license to the Patent Rights of M.I.T. Case 4167 for
      use
      with certain hybridomas, under the Collaborative Research Agreement between
      Centocor and M.I.T. dated November 14, 1988 as attached hereto as Appendix
      C.
      M.I.T. agrees that it will not renew the Collaboration Research Agreement as
      provided in Paragraph 2 thereof.

     

    2.3          
      In
      order
      to establish a period of exclusivity for LICENSEE, M.I.T. hereby agrees that
      with the exception of the rights granted or optioned to Centocor, it shall
      not
      grant any other license to make, have made, use, lease and sell Licensed
      Products or to utilize Licensed Processes during the period of time commencing
      with the Effective Date of this Agreement and terminating with the first to
      occur of:

     

    
      	 	
              (a)

            	
              for
                each type of Licensed Product the expiration of Twelve (12) years
                after
                the first commercial sale of that Licensed Product;
                or

            

    

     

    
      	 	
              (b)

            	
              the
                expiration of Sixteen (16) years after the Effective Date of this
                Agreement;

            

    

     

    provided,
      however, that for any Licensed Product for which an application for premarket
      approval has been submitted to the U.S. FDA prior to July 1, 2007, the time
      spent by the FDA reviewing said application(s) for that Licensed Product shall
      be added to the period of exclusivity which would otherwise apply.

     

    2.4          
      At
      the end
      of the exclusive period, the license granted hereunder shall become nonexclusive
      and shall extend to the end of the term or terms for which any Patent Rights
      are
      issued, unless sooner terminated as hereinafter provided, or unless the parties
      agree to extend the period of exclusivity.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    2.5          
      M.I.T.
      and
      Whitehead also agree to bring to the attention of LICENSEE any inventions which
      relate to [***] which arise prior to December 31, 1994 from the M.I.T. or
      Whitehead laboratories of any of the inventors of the Patent Rights listed
      in
      Appendix A. LICENSEE shall have a three month option, dating from the date
      at
      which any such invention is revealed to LICENSEE, to begin negotiations with
      M.I.T. for an exclusive license to such invention. If such negotiations are
      begun at LICENSEE’s request, LICENSEE shall have an additional three month
      option to negotiate in good faith for an exclusive license to the invention.
      LICENSEE’s options under this Paragraph 2.5 shall, however, be subject to any
      options or licenses granted under a research agreement with sponsors of the
      research leading to such invention, and the terms of such research agreements
      shall not be limited by the provisions of this Paragraph 2.5. M.I.T. and
      Whitehead shall use their best reasonable efforts to notify LICENSEE of any
      planned or completed sponsorship agreements, other than those involving U.S.
      Government sponsorship, in the field of [***], subject, however, to any
      confidentiality provisions with sponsors that might limit such
      notification.

     

    2.6          
      LICENSEE
      agrees that Licensed Products leased or sold in the United States shall be
      manufactured substantially in the United States.

     

    2.7          
      Whitehead
      and M.I.T. reserve the right to practice under the Patent Rights and to use
      and
      distribute the Tangible Property for their noncommercial research purposes
      under
      a Materials Transfer agreement similar to that in Appendix D. M.I.T. and
      Whitehead shall use their best reasonable efforts to notify LICENSEE of any
      Tangible Property distributed to third parties.

     

    2.8          
      LICENSEE
      shall have the right to enter into sublicensing agreements for the rights,
      privileges and licenses granted hereunder only during the exclusive period
      of
      this Agreement. Such sublicensees may extend past the expiration date of the
      exclusive period of this Agreement, but any exclusivity of such sublicenses
      will
      expire upon the expiration of LICENSEE’s exclusivity.

     

    2.9          
      LICENSEE
      hereby agrees that every sublicensing agreement to which it shall be a party
      and
      which shall relate to the rights, privileges and license granted hereunder
      shall
      contain a statement setting forth the date upon which LICENSEE’s exclusive
      rights, privileges and license hereunder shall terminate.

     

    2.10          
      LICENSEE
      agrees that any sublicenses granted by it shall provide that the obligations
      to
      M.I.T. and Whitehead of Articles II, V, VII, VIII, IX, X, XII, XIII, and XV
      of
      this Agreement shall be binding upon the sublicensee as if it were a party
      to
      this Agreement. LICENSEE further agrees to attach copies of these Articles
      to
      sublicense agreements.

     

    2.11          
      LICENSEE
      agrees to forward to M.I.T. a copy of any and all fully executed sublicense
      agreements, and further agrees to forward to M.I.T. annually a copy of such
      reports received by LICENSEE from its sublicensees during the preceding twelve
      (12) month period under the sublicensee as shall be pertinent to a royalty
      accounting under said sublicense agreements.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    2.12          
      LICENSEE
      shall not receive from sublicensees anything of value in lieu of cash payments
      in consideration for any sublicense under this Agreement, without the express
      prior written permission of M.I.T..

     

    2.13          
      The
      license granted hereunder shall not be construed to confer any rights upon
      LICENSEE by implication, estoppel or otherwise as to any technology not
      specifically set forth in Appendix A hereof and Paragraph 2.5.

     

    ARTICLE
      III - DUE
      DILIGENCE

     

    3.1          
      LICENSEE
      shall use its best efforts to bring one or more Licensed Products or Licensed
      Processes to market through a thorough, vigorous and diligent program for
      exploitation of the Patent Rights.

     

    3.2          
      In
      addition, LICENSEE shall adhere to the following milestones:

     

    
      	 	
              (a)

            	
              LICENSEE
                shall deliver to M.I.T. on or before [***] on or before the ninetieth
                (90th) day following the close of LICENSEE’s fiscal
                year.

            

    

     

    
      	 	
              (b)

            	
              ARIAD
                PHARMACEUTICALS, INC. (LICENSEE) shall have received at least
                [***].

            

    

     

    
      	 	
              (c)

            	
              ARIAD
                PHARMACEUTICALS, INC. (LICENSEE) shall have received a cumulative
                total of
                at least [***].

            

    

     

    
      	 	
              (d)

            	
              LICENSEE
                shall, within six (6) months of a request by a suitable sublicensee
                willing to take a sublicense upon reasonable business terms, grant
                at
                least one sublicense to the Patent Rights and Tangible Property for
                sale
                of Licensed Products as research reagents with appropriate protection
                of
                LICENSEE’s commercial interests. Failure to reach such an agreement within
                six (6) months after a bona fide request shall allow M.I.T. to grant
                a
                license to the Patent Rights to the requestor for sale of research
                reagents on terms no more favorable than those of paragraph 4.1(d)
                below.

            

    

     

    
      	 	
              (e)

            	
              In
                any calendar year after [***] that LICENSEE has not made at least
                [***] in
                Net Sales of Licensed Product, LICENSEE shall have invested a minimum
                of
                [***].

            

    

     

    3.3          
      LICENSEE’s
      failure to perform in accordance with Paragraphs 3.1 and 3.2 above shall be
      grounds for M.I.T. to terminate this Agreement pursuant to Paragraph 13.3
      hereof. 

     

    ARTICLE
      IV
      - ROYALTIES

     

    4.1          
      For
      the
      rights, privileges and license granted hereunder, LICENSEE shall pay royalties
      to M.I.T. in the manner hereinafter provided to the end of the term of the
      Patent Rights or until this Agreement shall be terminated as hereinafter
      provided:

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    
      	 	
              (a)

            	
              License
                Issue Fee of [***], which said License Issue Fee shall be deemed
                earned
                and due thirty days after the execution of this
                Agreement.

            

    

     

    
      	 	
              (b)

            	
              License
                Maintenance Fees of [***]per year payable on [***]and on January
                1 of each
                year thereafter until the [***]. Following the submission of such
                [***],
                the License Maintenance Fees shall be [***] per year beginning January
                1
                of the year following the submission. However, beginning [***], the
                License Maintenance Fees shall be [***] per year [***] has been submitted
                by LICENSEE. The License Maintenance Fee for a given year shall be
                fully
                creditable against any Running Royalties subsequently
                due.

            

    

     

    
      	 	
              (c)

            	
              A
                one-time Milestone Fee of [***] payable within ninety (90) days after
                LICENSEE receives approval to [***] on a Licensed Product based upon
                its
                [***].

            

    

     

    
      	 	
              (d)

            	
              Running
                Royalties in an amount equal to [***] of the Net Sales of Licensed
                Products and Licensed Processes used, leased or sold by and/or for
                LICENSEE which are covered [***] of the Patent Rights in any country
                in
                which the Licensed Products and/or Licensed Processes are made, used,
                leased or sold; and Running Royalties in an amount equal to [***]
                of the
                Net Sales of Licensed Products and Licensed Processes used, leased
                or sold
                by and/or for LICENSFF which are covered [***] of the Patent Rights
                in any
                country in which the Licensed Products and/or Licensed Processes
                are made,
                used, leased or sold. The provisions of this paragraph shall not
                apply to
                any Licensed Products leased or sold by LICENSEE or its sublicensees
                for
                use as research reagents.

            

    

     

    
      	 	
              (e)

            	
              Running
                Royalties in an amount equal to [***] of the Net Sales price of Licensed
                Products sold by or for LICENSER, or its sublicensees for use as
                research
                reagents.

            

    

     

    
      	 	
              (f)

            	
              [***]
                of any payments made to LICENSEE for sublicensing of the Patent Rights
                and/or Tangible Property. This subparagraph 4.1(f) shall not apply,
                however, to royalties paid to LICENSEE by sublicensee(s) on the Net
                Sales
                of Licensed Products sold by sublicensee(s) for use as research reagents,
                which shall fall under subparagraph 4.1(e)
                above.

            

    

     

    4.2          
      The
      License Issue Fee, Milestone Fee and all License Maintenance Fees shall be
      cumulatively creditable against Running Royalties.

     

    4.3          
      All
      patent
      costs incurred prior to July 1, 1991 and reimbursed by LICENSEE under Article
      VI
      shall be creditable against Running Royalties except for Running royalties
      on
      research reagents. [***] of patent costs incurred after July 1, 1991 shall
      be
      creditable against Running Royalties except for Running Royalties on research
      reagents.

     

    Portions
      of this Exhibit were omitted and have been filed separately with the Secretary
      of the Commission pursuant to the Company’s application requesting confidential
      treatment under Rule 24b-2 of the Securities Exchange Act of
      1934.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    4.4          
      The
      definitions of Paragraphs 1.3 and 1.4 notwithstanding, after [***] Running
      Royalties shall be due on the Net Sales of a Licensed Product only if the
      Licensed Product is covered [***].

     

    4.5          
      LICENSEE
      shall be entitled to credit [***] of the royalties paid to third parties for
      the
      use, lease or sale of a Licensed Product or Licensed Process by LICENSEE against
      the Running Royalties for that Licensed Product or Licensed Process due under
      subparagraph 4.1(d) above; provided, however that the amount credited shall
      not
      reduce the Running Royalty paid below [***] for the Licensed Product or Licensed
      Process covered [***], and [***] if the Licensed Product or Licensed Process
      is
      covered [***].

     

    4.6          
      In
      no
      instance shall the amount paid to M.I.T. in total in a given year be less than
      the License Maintenance Fee for that year.

     

    4.7          
      All
      payments due hereunder shall be paid in full, without deduction of taxes or
      other fees which may be imposed by any government and which shall be paid by
      LICENSEE.

     

    4.8          
      No
      multiple royalties shall be payable because any Licensed Product, its
      manufacture, use, lease or sale are or shall be covered by more than one patent
      application or patent licensed under this Agreement.

     

    4.9          
      Royalty
      payments shall be paid in United States dollars in Cambridge, Massachusetts,
      or
      at such other place as M.I.T. may reasonably designate consistent with the
      laws
      and regulations controlling in any foreign country. If any currency conversion
      shall be required in connection wish the payment of royalties hereunder, such
      conversion shall be made by using the exchange rate prevailing at the Chase
      Manhattan Bank (N.A.) on the last business day of the calendar quarterly
      reporting period to which such royalty payments relate.

     

    ARTICLE
      V
      - REPORTS
      AND RECORDS

     

    5.1          
      LICENSEE,
      within sixty (60) days after March 31, June 30, September 30 and December 31,
      of
      each year, shall deliver to M.I.T. true and accurate reports, giving such
      particulars of the business conducted by LICENSEE and its sublicensees during
      the preceding three-month period under this Agreement as shall be pertinent
      to a
      royalty accounting hereunder. These shall include at least the
      following:

     

    
      	 	
              (a)

            	
              number
                of Licensed Products manufactured and
                sold.

            

    

     

    
      	 	
              (b)

            	
              total
                billings for Licensed Products
                sold.

            

    

     

    
      	 	
              (c)

            	
              accounting
                for all Licensed Processes used or
                sold.

            

    

     

    
      	 	
              (d)

            	
              deductions
                applicable as provided in Paragraph
                1.5.

            

    

     

    
      	 	
              (e)

            	
              total
                royalties due.

            

    

     

    
      	 	
              (f)

            	
              names
                and addresses of all sublicensees of
                LICENSEE.

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    5.2          
      With
      each
      such report submitted, LICENSEE shall pay to M.I.T. the royalties due and
      payable under this Agreement. If no royalties shall be due, LICENSEE shall
      so
      report.

     

    5.3          
      On
      or
      before the ninetieth (90th) day following the close of LICENSEE’s fiscal year,
      LICENSEE shall provide M.I.T. with LICENSEE’s certified financial statements for
      the preceding fiscal year including, at a minimum, a Balance Sheet and an
      Operating Statement.

     

    5.4          
      The
      royalty payments set forth in this Agreement shall, if overdue, bear interest
      until payment at a per annum rate two percent (2%) above the prime rate in
      effect at the Chase Manhattan Bank (N.A.) on the due date. The payment of such
      interest shall not foreclose M.I.T. from exercising any other rights it may
      have
      as a consequence of the lateness of any payment.

     

    ARTICLE
      VI
      - PATENT
      PROSECUTION

     

    6.1          
      M.I.T.
      (and/or Whitehead, as appropriate, depending on ownership of the individual
      Patent Rights) shall apply for, seek prompt issuance of, and maintain during
      the
      term of this Agreement the Patent Rights in the United States and in the foreign
      countries listed in Appendix B hereto. Appendix B may be amended by verbal
      agreement of both parties, such agreement to be confirmed in writing within
      ten
      (10) days. The prosecution, filing and maintenance of all Patent Rights patents
      and applications shall be the primary responsibility of M.I.T. (and/or
      Whitehead); provided, however, LICENSEE shall have reasonable opportunities
      to
      advise M.I.T. (and/or Whitehead) and shall cooperate with M.I.T. (and/or
      Whitehead) in such prosecution, filing and maintenance.

     

    6.2          
      Payment
      of
      all fees and costs relating to the filing, prosecution, and maintenance of
      the
      Patent Rights shall be the responsibility of LICENSEE, whether such fees and
      costs were incurred before or after the date of this Agreement. Such payments
      shall be creditable as specified in Paragraphs 4.2 and 4.3. For fees and costs
      incurred prior to July 1, 1991, LICENSEE shall reimburse M.I.T. and Whitehead
      on
      the following schedule:

     

    
      
        	
                25%
                  of total:

              	
                30
                  days after billing

              
	 	 
	
                25%
                  of total:

              	
                January
                  15, 1992

              
	 	 
	
                25%
                  of total:

              	
                July
                  15, 1992

              
	 	 
	
                25%
                  of total:

              	
                January
                  15, 1993

              

      

    

     

    Fees
      and
      costs incurred after July 1, 1991 shall be reimbursed within 30 days after
      billing.

     

    ARTICLE
      VII - INFRINGEMENT

     

    7.1          
      LICENSEE,
      M.I.T. and Whitehead shall promptly inform each other of any alleged
      infringement of the Patent Rights by a third party and of any available evidence
      thereof.

     

    7.2          
      During
      the
      term of this Agreement, LICENSEE shall have the right, but shall not be
      obligated, to prosecute at its own expense any such infringements of the Patent
      Rights and in furtherance of such right, M.I.T. and Whitehead hereby agree
      that
      LICENSEE may include 

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    M.I.T.
      or
      Whitehead as party plaintiffs in any such suit without expense to M.I.T. or
      Whitehead. The total cost of any such infringement action commenced or defended
      solely by LICENSEE shall be borne by LICENSEE. LICENSEE may, for such purposes,
      use the name of M.I.T. or Whitehead as party plaintiffs provided, however,
      that
      such right to bring an infringement action shall remain in effect only for
      so
      long as the license granted herein remains exclusive. No settlement, consent
      judgment or other voluntary final disposition of the suit may be entered into
      without the consent of M.I.T. and Whitehead, which consent shall not
      unreasonably be withheld. LICENSEE shall indemnify M.I.T. and Whitehead against
      any order for costs associated with the litigation that may be made against
      M.I.T. or Whitehead in such proceedings.

     

    7.3          
      In
      the
      event that LICENSEE shall undertake the enforcement and/or defense of the Patent
      Rights by litigation, LICENSEE may withhold up to [***] of the royalties
      otherwise thereafter due M.I.T. hereunder and apply the same toward
      reimbursement of up to [***] of LICENSEE’s expenses, including reasonable
      attorney’s fees, in connection therewith. Any recovery of damages by LICENSEE
      for any such suit shall be applied pro
      rata
      in
      satisfaction of (i) any unreimbursed expenses and legal fees of LICENSEE
      relating to the suit; and (ii) any royalties due M.I.T. and withheld by LICENSEE
      and applied pursuant to this Paragraph 7.3. The balance remaining from any
      such
      recovery shall be divided between LICENSEE and M.I.T. in the proportion of
      [***].

     

    7.4          
      If
      within
      six (6) months after having been notified of any alleged infringement, LICENSEE
      shall have been unsuccessful in persuading the alleged infringer to desist
      and
      shall not have brought and shall not be diligently prosecuting an infringement
      action, or if LICENSEE shall notify M.I.T. at any time prior thereto of its
      intention not to bring suit against any alleged infringer, then, and in those
      events only, M.I.T. or Whitehead, as appropriate) shall have the right, but
      shall not be obligated, to prosecute at its own expense any infringement of
      the
      Patent Rights, and, in furtherance of such right, LICENSEE hereby agrees that
      M.I.T. (or Whitehead) may include LICENSEE as a party plaintiff in any such
      suit, without expense to LICENSEE. The total cost of any such infringement
      action commenced or defended solely by M.I.T. (or Whitehead) shall be borne
      by
      M.I.T. (or Whitehead), and M.I.T. (or Whitehead) shall keep any recovery or
      damages for past infringement derived therefrom. No settlement, consent judgment
      or other voluntary final disposition of the suit maybe entered into without
      the
      consent of LICENSEE, which consent shall not unreasonable be
      withheld.

     

    7.5          
      In
      the
      event that a declaratory judgment action alleging invalidity or noninfringement
      of any of the Patent Rights shall be brought against LICENSEE, M.I.T. (or
      Whitehead), at its option, shall have the right, within thirty (30) days after
      commencement of such action, to intervene and take over the sole defense of
      the
      action at its own expense.

     

    7.6          
      In
      any
      infringement suit as any party may institute to enforce the Patent Rights
      pursuant to this Agreement, the other parties hereto shall, at the request
      and
      expense of the party initiating such suit, cooperate in all respects and, to
      the
      extent possible, have its employees testify when requested and make available
      relevant records, papers, information, samples, specimens, and the
      like.

     

    7.7          
      LICENSEE,
      during the exclusive period of this Agreement, shall have the sole right in
      accordance with the terms and conditions herein to sublicense any alleged
      infringer for 

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    future
      use
      of the Patent Rights. Any upfront fees paid to LICENSEE as part of such
      sublicense shall be handled in accordance with subparagraph 4.1(f).

     

    ARTICLE
      VIII - PRODUCT
      LIABILITY

     

    8.1          
      LICENSEE
      shall at all times during the tern of this Agreement and thereafter, indemnify,
      defend and hold M.I.T. and Whitehead, their trustees, officers, employees and
      affiliates, harmless against all claims and expenses, including legal expenses
      and reasonable attorneys’ fees, arising out of the death of or injury to any
      person or persons or out of any damage to property and against any other claim,
      proceeding, demand, expense and liability of any kind whatsoever resulting
      from
      the production, manufacture, sale, use, lease, consumption or advertisement
      of
      the Licensed Product(s) and/or Licensed Process(es) or arising from any
      obligation of LICENSEE hereunder.

     

    8.2          
      LICENSEE
      shall obtain prior to the first use of a Licensed Product or Licensed Process
      on
      humans and carry in full force and effect liability insurance which shall
      protect LICENSEE, M.I.T. and Whitehead in regard to events covered by Paragraph
      8.1 above.

     

    8.3          
      EXCEPT
      AS
      OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T. AND WHITEHEAD MAKE
      NO
      REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
      INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
      PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR
      PENDING.

     

    ARTICLE
      IX
      - EXPORT
      CONTROLS

     

    It
      is
      understood that M.I.T. and Whitehead are subject to United States laws and
      regulations controlling the export of technical data, computer software,
      laboratory prototypes and other commodities (including the Arms Export Control
      Act, as amended and the Export Administration Act of 1979), and that its
      obligations hereunder are contingent on compliance with applicable United States
      export laws and regulations. The transfer of certain technical data and
      commodities may require a license from the cognizant agency of the United States
      Government and/or written assurances by LICENSEE that LICENSEE shall not export
      data or commodities to certain foreign countries without prior approval of
      such
      agency. M.I.T. neither represents that a license shall not be required nor
      that,
      if required, it shall be issued.

     

    ARTICLE
      X
      - NON-USE
      OF
      NAMES

     

    LICENSEE
      shall not use the names of the Massachusetts Institute of Technology nor of
      the
      Whitehead Institute nor any of their employees, nor any adaptation thereof,
      in
      any advertising, promotional or sales literature without prior written consent
      obtained from M.I.T. in each case, except that LICENSEE may state that it is
      licensed by Whitehead or M.I.T. under one or more of the patents and/or
      applications comprising the Patent Rights.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      XI
      - ASSIGNMENT

     

    The
      rights
      of ARIAD under this Agreement may not be assigned and the duties of ARIAD under
      this Agreement may not be delegated without the prior written consent of M.I.T.
      and Whitehead, except that ARIAD may assign this Agreement to an entity,
      acceptable to M.I.T. and Whitehead, with which it merges or consolidates or
      which ARIAD controls, or to which substantially all of its assets relating
      to
      the Patent Rights are sold or otherwise transferred or to a partnership of
      which
      ARIAD or any of its affiliates in the general partner.

     

    ARTICLE
      XII - ARBITRATION

     

    12.1          
      Any
      and
      all claims, disputes or controversies arising under, out of, or in connection
      with this Agreement, including any dispute relating to patent validity or
      infringement, which have not been resolved by good faith negotiations between
      the parties, shall be resolved by final and binding arbitration in Boston,
      Massachusetts under the rules of the American Arbitration Association, or the
      Patent Arbitration Rules if applicable, then obtaining. The arbitrators shall
      have no power to add to, subtract from or modify any of the terms or conditions
      of this Agreement. Any award rendered in such arbitration may be enforced by
      either party in either the courts of the Commonwealth of Massachusetts or in
      the
      United States District Court for the District of Massachusetts, to whose
      jurisdiction for such purposes M.I.T., Whitehead and LICENSEE each hereby
      irrevocably consents and submits.

     

    12.2          
      Notwithstanding
      the foregoing, nothing in this Article shall be construed to waive any rights
      or
      timely performance of any obligations existing under this
      Agreement.

     

    ARTICLE
      XIII - TERMINATION

     

    13.1          
      If
      LICENSEE shall cease to carry on its business, this Agreement shall terminate
      upon notice by M.I.T.

     

    13.2          
      Should
      LICENSEE fail to pay M.I.T. royalties due and payable hereunder, M.I.T. shall
      have the right to terminate this Agreement on thirty (30) days’ notice, unless
      LICENSEE shall pay M.I.T. within the thirty (30) day period, all such royalties
      and interest due and payable. Upon the expiration of the thirty (30) day period,
      if LICENSEE shall not have paid all such royalties and interest due and payable,
      the rights, privileges and license granted hereunder shall
      terminate.

     

    13.3          
      Upon
      any
      material breach or default of this Agreement by LICENSEE, other than those
      occurrences set out in Paragraphs 13.1 and 13.2 hereinabove, which shall always
      take precedence in that order over any material breach or default referred
      to in
      this Paragraph 13.3, M.I.T. shall have the right to terminate this Agreement
      and
      the rights, privileges and license granted hereunder by ninety (90) days’ notice
      to LICENSEE. Such termination shall become effective unless LICENSEE shall
      have
      cured any such breach or default prior to the expiration of the ninety (90)
      day
      period.

     

    13.4          
      LICENSEE
      shall have the right to terminate this Agreement at any time on six (6) months’
notice to M.I.T., and upon payment of all amounts due M.I.T. through the
      effective date of the termination.

     

    Portions
      of this Exhibit were omitted and have been filed separately with the Secretary
      of the Commission pursuant to the Company’s application requesting confidential
      treatment under Rule 24b-2 of the Securities Exchange Act of
      1934.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    13.5          
      Upon
      termination of this Agreement for any reason, nothing herein shall be construed
      to release either party from any obligation that matured prior to the effective
      date of such termination. LICENSEE and any sublicensee thereof may, however,
      after the effective date of such termination, sell all Licensed Products, and
      complete Licensed Products in the process of manufacture at the time of such
      termination and sell the same, provided that LICENSEE shall pay to M.I.T. the
      royalties thereon as required by Article IV of this Agreement and shall submit
      the reports required by Article V hereof on the sales of Licensed
      Products.

     

    13.6          
      Upon
      termination of this Agreement for any reason, any sublicensee not then in
      default shall have the right to seek a license from M.I.T.

     

    13.7          
      LICENSEE
      shall have the right, upon written notice to M.I.T., to separately terminate
      its
      license to any independent patent application or patent of the Patent
      Rights.

     

    ARTICLE
      XIV - PAYMENTS
      NOTICES AND OTHER COMMUNICATIONS

     

    Any
      payment, notice or other communication pursuant to this Agreement shall be
      sufficiently made or given on the date of mailing if sent to such party by
      certified first class mail, postage prepaid, addressed to it at its address
      below or as it shall designate by written notice given to the other
      party:

     

    In
      the
      case of M.I.T.:

     

    Director

    Technology
      Licensing Office

    Massachusetts
      Institute of Technology

    Room
      E32-300

    Cambridge,
      Massachusetts 02139

     

    In
      the
      case of WHITEHEAD:

     

    Vice
      President

    Whitehead
      Institute

    Nine
      Cambridge Center 

    Cambridge,
      MA 02142

     

    In
      the
      case of LICENSEE:

     

    Harvey
      J.
      Berger, M.D.

    Chairman
      and Chief Executive Officer 

    ARIAD
      Pharmaceuticals, Inc.

    687
      Wetherby Lane

    Devon,
      PA
      19333

     

    or
      as
      amended in writing from time to time by any party.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

       

    

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      XV
      - MISCELLANEOUS
      PROVISIONS

     

    15.1          
      This
      Agreement shall be construed, governed, interpreted and applied in accordance
      with the laws of the Commonwealth of Massachusetts, U.S.A., except that
      questions affecting the construction and effect of any patent shall be
      determined by the law of the country in which the patent was
      granted.

     

    15.2          
      The
      parties hereto acknowledge that this Agreement sets forth the entire Agreement
      and understanding of the parties hereto as to the subject matter hereof, and
      shall not be subject to any change or modification except by the execution
      of a
      written instrument subscribed to by the parties hereto.

     

    15.3          
      The
      provisions of this Agreement are severable, and in the event that any provisions
      of this Agreement shall be determined to be invalid or unenforceable under
      any
      controlling body of the Law, such invalidity or unenforceability shall not
      in
      any way affect the validity or enforceability of the remaining provisions
      hereof.

     

    15.4          
      LICENSEE
      agrees to mark the Licensed Products sold in the United States with all
      applicable United States patent numbers. All Licensed Products shipped to or
      sold in other countries shall be marked in such a manner as to conform with
      the
      patent laws and practice of the country of manufacture or sale.

     

    15.5          
      The
      failure of any party to assert a right hereunder or to insist upon compliance
      with any term or condition of this Agreement shall not constitute a waiver
      of
      that right or excuse a similar subsequent failure to perform any such term
      or
      condition by the other parties.

     

    IN
      WITNESS
      WHEREOF, the parties have hereunto set their hands and seals and duly executed
      this Agreement the day and year set forth below.

     

    

    MASSACHUSETTS
      INSTITUTE OF TECHNOLOGY

    

    
      	
              By

            	
              /s/
                John T. PrestoN

            
	
              Name

            	
              John
                T. Preston

            
	
              Title

            	
              Director,
                Technology Licensing Office

            
	
              Date

            	
              8-26-91

            

    

    

    

    WHITEHEAD
      INSTITUTE

    

    
      	
              By

            	
              /s/
                John Pratt

            
	
              Name

            	
              John
                Pratt

            
	
              Title

            	
              Vice
                President

            
	
              Date

            	
              8/28/91

            

    

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    ARIAD
      PHARMACEUTICALS, INC.

    

    
      	
              By

            	
              /s/
                Harvey Berger, M.D.

            
	
              Name

            	
              Harvey
                J. Berger, M.D.

            
	
              Title

            	
              Chairman
                & Chief Executive Officer

            
	
              Date

            	
              8/19/91

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    APPENDIX
      A

     

    M.I.T.
      Case No. [***]

    U.S.S.N.
      [***] (Filed [***])

    (Owned
      by
      M.I.T. and the Whitehead Institute, jointly)

     

    FOREIGN
      FILING(S) 

     

    M.I.T.
      Case No. [***]:

    

    European
      Application No. [***] (Filed [***])

    (Claiming
      Austria, Belgium, Switzerland/Liechtenstein, Germany, France, Great Britain,
      Italy, Luxembourg, Netherlands, Sweden)

    

    Japanese
      Application No. PCT/[***] (Filed [***]) 

    

    M.I.T.
      Case No. [***]:

    

    Canadian
      Application No. [***] (Filed [***])

    European
      Application No. [***] (Filed [***])

    (Claiming
      Austria, Belgium, Switzerland/Liechtenstein, Germany, France, Great Britain,
      Italy, Luxembourg, Netherlands, Sweden)

    Japanese
      Application No. PCT/[***] (Filed [***])

    

    M.I.T.
      Case No. [***]
      (Whitehead No. [***])

    [***]

    U.S.S.N.
      [***] (Filed [***]) 

    (Owned
      by
      The Whitehead Institute)

    

    FOREIGN
      FILING(S)

    

    [***]

    

    

    M.I.T.
      Case No. [***]
      (Whitehead No. [***])
      

    [***]

    U.S.S.N.
      [***] (Filed [***])

    (Owned
      by
      The Whitehead Institute)

    

    FOREIGN
      FILING(S)

    

    European
      Application No. PCT/[***] (Filed [***])

    (Claiming
      Austria, Belgium, Switzerland/Liechtenstein, Germany, France, Great Britain,
      Italy, Luxembourg, Netherlands, Sweden)

    

    

    M.I.T.
      Case No. [***]
      (Whitehead No. [***])

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

     

    [***]

    U.S.S.N.
      [***] (Filed [***])

    (Owned
      by
      The Whitehead Institute and Harvard University, jointly. Harvard University
      has
      given M.I.T. the authority to license Harvard’s rights on Harvard’s behalf and
      has given Whitehead full rights to prosecute and defend the Patent
      Rights.)

    

    FOREIGN
      FILING (S)

    

    [***]

    

    M.I.T.
      Case [***]
      (Whitehead [***])

    [***]
      

    (Owned
      by
      The Whitehead Institute)

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

    APPENDIX
      B

     

    Foreign
      countries in which Patent Rights shall be filed, prosecuted and maintained
      in
      accordance with Article VI where legally possible:

     

     

    [***]

     

    [***]

     

    [***]

     

    [***]

     

    [***]

     

    [***]

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

    APPENDIX
      C

     

    
      	 	#l/LLN111/14/88 
	 	
              CentCollabResAgt
                

            

    

     

     

    COLLABORATIVE
      RESEARCH AGREEMENT

     

    This
      Agreement between Centocor, Inc. and the Massachusetts Institute of Technology
      (“M.I.T.”) defines the terms and conditions under which Centocor scientists will
      collaborate with Prof Phillip A. Sharp and colleagues in the Cancer Center
      at
      M.I.T. in the area of antibody gene expression (“The
      Collaboration”).

     

    Centocor
      and M.I.T. hereby agree as follows:

     

    1.            
      FIELD:
      The
      Field of the Collaboration is defined by the Work Statement attached hereto
      as
      Appendix A.

     

    2.            
      DURATION:
      The Collaboration shall begin on December 1, 1988 and terminate on November
      30,
      1991, unless sooner terminated by either party notifying the other, in writing,
      that it wishes to terminate the Collaboration. The Collaboration may be extended
      by written mutual consent.

     

    3.            
      EXCHANGE
      OF INFORMATION: During the Collaboration, each party shall provide the other
      with all data and other information that it develops under the
      Collaboration.

     

    4.            
      M.I.T.
      TANGIBLE PROPERTY: M.I.T. shall provide to Centocor certain biological materials
      (“M.I.T.”) developed before the Collaboration, for Centocor’s use in the
      Collaboration. Centocor shall not give samples, progeny, or derivatives of
      such
      M.I.T. Tangible Property to any third party except with the written permission
      of M.I.T.

     

    5.            
      BIOLOGICAL
      MATERIAL DEVELOPED UNDER THE COLLABORATION: Any biological material developed
      by
      one party under the Collaboration shall be provided to the other for its use
      under the Collaboration. Samples, progeny or derivatives of any biological
      materials developed under the Collaboration shall not be delivered to any third
      party without the written permission of the developing party, except as
      specified in Paragraph 8(c) below. Notwithstanding the foregoing, for hybridomas
      developed under this Collaboration which are of commercial value to Centocor
      and
      which are derived from hybridomas developed or obtained by Centocor outside
      of
      this Collaboration, Centocor shall not be requited to provide said hybridomas
      to
      MIT unless provision is specifically requested by MIT for specific purposes
      and,
      unless suitable cell line transfer agreements in the form of those contained
      in
      Appendix C are executed between the parties hereto.”

     

    6.            
      PUBLICATION:
      Either party shall be free to publish any of the results it obtains under the
      Collaboration, and shall acknowledge the contribution of the other party, or
      include the other 

     

    Portions
      of this Exhibit were omitted and have been filed separately with the Secretary
      of the Commission pursuant to the Company’s application requesting confidential
      treatment under Rule 24b-2 of the Securities Exchange Act of
      1934.

     

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

     

    party
      as
      co-author, as appropriate. The publishing party shall provide the other parry
      with a copy of manuscripts submitted for publication at least thirty days prior
      to publication, in order to allow the other party to identify potentially
      patentable material and request that a patent application be filed.

     

    7.            
      INVENTIONS:
      Any inventions made by Centocor personnel shall belong to Centocor, inventions
      made by M.I.T. personnel shall be owned by M.I.T. Inventions made jointly by
      M.I.T. and Centocor personnel shall belong jointly to M.I.T. and Centocor.
      Each
      party shall promptly notify the other if it makes an invention during the
      Collaboration, and if it intends to file a patent application on any such
      inventions. Copies of any such patent applications which are filed by one party
      shall be promptly provided to the other party.

     

    8.            
      PATENT
      AND
      LICENSING RIGHTS:

     

    (a)           
      During
      the
      Collaboration, M.I.T. shall grant to Centocor a royalty-free nonexclusive
      license to the Patent Rights of the M.I.T. Cases listed in Appendix B and to
      the
      M.I.T. Tangible Property for internal research and development use in the field
      of use of “Expression of Antibodies”. If Centocor does not terminate this
      Agreement at any time prior to October 31, 1991, the internal research and
      development use license to the Patent Rights and the M.I.T. Tangible Property
      shall be in perpetuity.

     

    (b)           
      M.I.T.
      shall have the right to use any biological property and inventions developed
      by
      Centocor under the Collaboration for its own internal uses, royalty-free in
      perpetuity.

     

    (c)           
      “Transferrable
      Property” is defined as any biological property developed by Centocor under the
      Collaboration, but excluding hybridomas developed by Centocor which produce
      antibody of commercial value to Centocor. “Licensable Centocor Patent .Rights”
shall mean patent rights to inventions made by Centocor under the Collaboration,
      but excluding claims to hybridomas producing antibody of commercial value to
      Centocor. M.I.T. shall have the right to license to third parties, only in
      conjunction with the Patent Rights to Appendix B, any Transferrable Property
      and
      Licensable Centocor Inventions. M.I.T. shall pay to Centocor twenty-five percent
      (25%) of the Net Royalties it receives from such licenses. (“Net Royalties” is
      defined as Gross Royalties minus 15% for administration and marketing, and
      minus
      any unreimbursed out-of-pocket patenting costs.)

     

    (d)           
      Centocor
      shall have a first option to an exclusive royalty-bearing license with suitable
      due diligence provisions, for certain Applications, to the M.I.T. Tangible
      Property, the Patent Rights of Appendix B, and any M.I.T. inventions or
      biological property developed under the Collaboration. An “Application” is
      defined as all hybridomas producing antibodies to a single antigen or directed
      to detection of a single disease state if all tests for that disease are based
      on the same antigen or set of antigens operating by the same basic mechanism
      in
      the disease state. The terms of Centocor’s option are as follows:

     

    (i)           
      Centocor
      shall have a first option for an exclusive license to all Applications for
      one
      year following the beginning of the Collaboration and an option for a
      non-exclusive license until one year following the end of the Collaboration.
      Thereafter, Centocor’s option shall be only to Applications for which M.I.T. has
      not previously granted a license to a third party.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

     

    (ii)           Centocor
      may exercise its option to an exclusive license for an Application only after
      Centocor demonstrates that it has developed a suitable hybridoma for that
      Application, or that it has an intensive development program in place
      specifically devoted to development of a hybridoma for that Application. In
      the
      latter event, Centocor’s license to the hybridoma shall terminate if a
      functional hybridoma is not developed by Centocor within two years of the
      effective date of the license.

     

    (iii)          If
      Centocor exercises its option to an exclusive license to an Application, the
      royalties shall be as follows:

     

    ((a))     
      For
      Applications using known hybridomas whose efficiency of production of antibody
      is increased by use of the Patent Rights of Appendix B or the M.I.T. Tangible
      Property and/or M.I.T. patents or M.I.T. biological property developed under
      the
      Collaboration (together defined as “M.I.T. Intellectual and Material Property”),
      royalties shall include a License Issue Fee of $10,000 per Application, and
      a
      Running Royalty of one-half of one percent (0.5%) of Centocor’s sales of product
      produced and sold using the M.I.T. Intellectual and Material
      Property.

     

    ((b))     
      For
      Applications using new hybridomas which could not be practically developed
      without use of the M.I.T. Intellectual and Material Property, a License Issue
      Fee of $25,000 per Application, and a Running Royalty of 2.5% of product
      sales.

     

    AGREED
      TO
      FOR:

     

    
      
        	
                MASSACHUSETTS
                  INSTITUTE

              	
                CENTOCOR,
                  INC.

              
	
                OF
                  TECHNOLOGY

              	 

      

       

      
        	By:	
                 /s/
                  John T. Preston

              	 	By:	
                By:
                  /s/ [Chairman of Board of Centocor]

              	 
	 	 	 	 	 	 
	Title:
                	
                Director,
                  Technology Licensing Office

              	 	Title:
                	
                Title:
                  Chairman of the Board

              	 
	 	 	 	 	 	 
	Date:
                	
                Nov.
                  14, 1998

              	 	Date:
                	
                Date:
                  Nov. , 1998

              	 

      

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

       

    

    
      
        
        

      

      
        22

        
          

        

      

      
        
        

      

    

     

    APPENDIX
      A

     

    WORK
      STATEMENT

     

    As
      part of
      a continuing collaboration between MIT scientists (represented by Dr. Phillip
      Sharp and Centocor), the MIT scientists will isolate and characterize cDNA
      clones representing cellular factors involved .in the regulation of
      immunoglobulin gene expression. Said cDNA clones will then be sent to Centocor
      where they will be used in one or more of the following ways:

     

    
      	 	
              a)

            	
              The
                cDNA clones will be used as probes to determine the level of expression
                of
                said factors in hybridoma and other cell
                lines.

            

    

     

    
      	 	
              b)

            	
              the
                cDNA clones will be expressed in hybridoma or other mammalian cells
                in
                order to study their effects on immunoglobulin
                production.

            

    

     

    
      	 	
              c)

            	
              the
                cDNA clones will be expressed in E. coli in order to obtain large
                quantities for study and for production of
                antisera.

            

    

     

    
      	 	
              d)

            	
              Recombinants
                of the cDNAs and otter activator genes may also be tested in the
                course of
                these experiments.

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        23

        
          

        

      

      
        
        

      

    

    APPENDIX
      D

     

    MASSACHUSETTS
      INSTITUTE OF TECHNOLOGY     Cambridge,
      Massachusetts 02139

     

    Date:
      ________________________

     

     

    
      
        	
                Biomaterials
                  Coordinator

              	 
	
                Technology
                  Licensing Office

              	
                Biology
                  Department

              
	
                Massachusetts
                  Institute of Technology

              	
                Massachusetts
                  Institute of Technology

              
	
                Building
                  E32-300

              	
                Building

              
	
                77
                  Massachusetts Ave.

              	
                77
                  Massachusetts Ave.

              
	
                Cambridge,
                  MA 02139

              	
                Cambridge,
                  MA 02139

              

      

    

     

    Subject:                    
      BIOLOGICAL
      MATERIAL TRANSFER AGREEMENT 

     

    Dear

     

    This
      is to
      acknowledge your request for ___________________________________________
      _____________________________________, which is owned by MASSACHUSETTS INSTITUTE
      OF TECHNOLOGY (M.I.T.). M.I.T. will provide this material to you, for your
      use
      in noncommercial scientific research only, under the following
      conditions:

     

    
      	 	
              1.

            	
              The
                Material covered by this Agreement includes_______________________,
                any
                additional progeny or derivatives which could not have been made
                but for
                the_______________________ and any related information and know-how
                which
                will be received under this
                agreement.

            

    

     

    
      	 	
              2.

            	
              The
                Material will be used only by you and by individuals working under
                your
                direct supervision in your Institution, and will not be transferred,
                distributed or released to any other
                person.

            

    

     

    
      	 	
              3.

            	
              The
                Material will be used only for noncommercial, publishable research
                purposes. It will not be used on any research to be used for the
                development of any commercial product, including drug screening or
                development for commercial purposes or on behalf of any commercial
                entity.

            

    

     

    
      	 	
              4.

            	
              You
                will be free to publish any research results using the Material.
                We would
                appreciate your acknowledging in such publication(s) MIT and its
                personnel
                as scientifically appropriate, and providing MIT with copies of such
                publication(s).

            

    

     

    
      	 	
              5.

            	
              The
                Material is made available for investigational use only in laboratory
                animals or in in
                vitro,
                experiments and will not be used in humans or for any other
                purpose.

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        24

        
          

        

      

      
        
        

      

    

     

    
      	 	
              6.

            	
              All
                characteristics of the Material are not fully understood and its
                use may
                involve risks or dangers that are not known or fully appreciated.
                The
                Material is being provided without warranty of any sort, express
                or
                implied.

            

    

     

    
      	 	
              7.

            	
              You
                and your Institution will use the Material in compliance with all
                laws and
                governmental regulations and guidelines applicable to the Material
                and
                will comply with all NIH guidelines and other relevant NIH instructions.
                In particular:

            

    

     

    
      	 	
              A)

            	
              Your
                laboratory has been reviewed by its institutional biohazards committee
                (IBC) which has certified that facilities, procedures, and the training
                and expertise of the personnel involved are
                adequate;

            

    

     

    
      	 	
              B)

            	
              Your
                laboratory has received the appropriate approvals and has registered
                its
                rDNA program with the IBC; and

            

    

     

    
      	 	
              C)

            	
              A
                copy of this letter is on file with your laboratory’s
                IBC.

            

    

     

    
      	 	
              8.

            	
              You
                will hold MASSACHUSETTS
                INSTITUTE OF TECHNOLOGY (M.I.T.) and
                its employees harmless from any loss, claim, damage or liability,
                of any
                kind, which may arise from or in connection with this Agreement or
                the
                use, handling or storage of the Material. In no case shall M.I.T,
                or
                Professor ______________ be liable for any use by you, by individuals
                working under your direct supervision, or by your Institution, of
                the
                Material or any loss, claim, damage or liability, of any kind, which
                may
                arise from or in connection with this Agreement or the use, handling
                or
                storage of the Material.

            

    

     

    
      	 	
              9.

            	
              You
                understand that no other right or license to this Material or to
                its use
                is granted or implied as a result of our sending the Material to
                you.

            

    

     

    
      	 	
              10.

            	
              At
                the request of MASSACHUSETTS
                INSTITUTE OF TECHNOLOGY,
                unused Material will be returned to M.I.T. or
                destroyed.

            

    

     

    Research
      Project: Studies on the activation and differentiation of monocytic
      cells.

     

    If
      you
      agree to accept the Material under the above conditions, please sign the
      Agreement, have it signed by an authorized representative of your Institution
      and return it to:

     

    _________________________________

    _________________________________

    _________________________________

    _________________________________

    _________________________________

     

    Portions
      of this Exhibit were omitted and have been filed separately with the Secretary
      of the Commission pursuant to the Company’s application requesting confidential
      treatment under Rule 24b-2 of the Securities Exchange Act of
      1934.

     

    
      
        
        

      

      
        25

        
          

        

      

      
        
        

      

    

     

    The
      Material will be sent to you as soon as possible after the receipt of the signed
      agreement.

     

    Sincerely,
      

     

     

    Accepted:

     

    REQUESTER

    INSTITUTION
      ______________________________

     

    
      
        	
                By:
                  _____________________________

              	
                By:_____________________________

              
	
                (Signature)

              	
                (Signature)

              
	 	 
	
                By:_____________________________

              	
                By:_____________________________

              
	
                (Printed
                  Name)

              	
                (Authorized
                  Representative’s 

              
	 	
                Printed
                  Name)

              
	 	 
	
                Date:____________________________

              	
                Date:____________________________

              

      

      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

       

    

    
      
        
        

      

      
        26

        
          

        

      

      
        
        

      

    

     

    FIRST
      AMENDMENT

    

    This
      amendment, dated November 20, 1991, is to the License Agreement dated August
      19,
      1991 between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, the WHITEHEAD INSTITUTE,
      and
      ARIAD PHARMACEUTICALS, INC.

    

    The
      parties agree that the License Agreement shall be amended as follows in order
      to
      acknowledge Harvard University’s ownership of certain Patent
      Rights:

    

    
      	 	
              1.

            	
              The
                following paragraph shall be added to the WITNESSETH
                section:

            

      	 	 	 

      	 	 	“WHEREAS,
              M.I.T. Case No. [***] (Whitehead No. [***]) “[***] is jointly owned by
              Harvard University, and Harvard University (Harvard) has authorized
              M.I.T.
              to act as its sole and exclusive agent for the purposes of licensing
              Harvard’s rights in the Patent Rights and has authorized M.I.T. to enter
              into this licensing agreement on Harvard’s
              behalf;

    

     

    
      	 	
              2.

            	
              The
                word “Harvard” shall be added after “Whitehead,” in the first sentence of
                Paragraph 1.2.

            

    

    

    
      	 	
              3.

            	
              The
                words “and Harvard” shall be added after “Whitehead and M.I.T.” and
                “M.I.T. and Whithead” in Paragraph
                2.7.

            

    

    

    
      	 	
              4.

            	
              The
                words “and/or Harvard” shall be added after the words “and/or Whitehead”
                in all instances in Paragraph 6.1.

            

    

    

    
      	 	
              5.

            	
              The
                words “and Harvard” shall be added after the words “M.I.T. and Whitehead”
                in Paragraphs 7.1 and 7.2. The words “or Harvard shall be added after the
                words “M.I.T. or Harvard” in Paragraph
                7.2.

            

    

    

    
      	 	
              6.

            	
              The
                words “and Harvard” shall be added after the words “M.I.T. and Whitehead”
                in all instances in Paragraphs 8.1, 8.2 and
                8.3.

            

    

    

    
      	 	
              7.

            	
              The
                words “nor of Harvard University” shall be added after “nor of the
                Whitehead Institute”, and the words “or Harvard” shall be added after the
                words “Whitehead or M.I.T. in Section
                X.

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

       

    

    
      
        
        

      

      
        27

        
          

        

      

      
        
        

      

    

    IN
      WITNESS
      WHEREOF, the parties have hereunto set their hands and seals and duly executed
      this Agreement the day and year set forth below.

    

    

      

      MASSACHUSETTS
        INSTITUTE OF TECHNOLOGY

      

      
        	
                By

              	
                /s/
                  John T. Preston

              
	
                Name

              	
                John
                  T. Preston

              
	
                Title

              	
                Director,
                  Technology Licensing Office

              
	
                Date

              	
                11-11-91

              

      

      

      WHITEHEAD
        INSTITUTE

      

      
        	
                By

              	
                /s/
                  John Pratt

              
	
                Name

              	
                John
                  Pratt

              
	
                Title

              	
                Vice
                  President

              
	
                Date

              	
                11/20/91

              

      

      

      

      ARIAD
        PHARMACEUTICALS, INC.

      

      
        	
                By

              	
                /s/
                  Harvey Berger

              
	
                Name

              	
                Harvey
                  J. Berger

              
	
                Title

              	
                Chairman
                  & CEO

              
	
                Date

              	
                11/20/91

              

      

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        28

        
          

        

      

      
        
        

      

    

    SECOND
      AMENDMENT TO LICENSE AGREEMENT

    

    This
      Second Amendment to License Agreement (“Second Amendment to License Agreement”)
      is made and entered into as of this 2nd day of January, 2002, (the “Effective
      Date”) by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a corporation
      organized and existing under the laws of the Commonwealth of Massachusetts
      and
      having its principal offices at 77 Massachusetts Avenue, Cambridge,
      Massachusetts (hereinafter referred to as “M.I.T.”), and the WHITEHEAD
      INSTITUTE, a corporation organized and existing under the laws of Delaware
      and
      having its principal offices at Nine Cambridge Center, Cambridge, Massachusetts
      (hereinafter referred to as “Whitehead”) and ARIAD PHARMACEUTICALS, INC., a
      corporation duly organized under the laws of Delaware and having its principal
      offices at 20 Landsdowne Street, Cambridge, Massachusetts (hereinafter referred
      to as “LICENSEE”).

    

      
WHEREAS,
      M.I.T., WHITEHEAD and LICENSEE entered into that certain License Agreement
      dated
      August 19, 1991, and amended same effective November 20, 1991 (collectively,
      the
“Agreement”); and

    

    WHEREAS,
      the parties to the Agreement desire to amend certain terms of the Agreement,
      to
      add certain terms to the Agreement and to confirm the validity and effectiveness
      of the remaining terms and conditions set forth in the Agreement, all as further
      set forth herein.

    

    NOW,
      THEREFORE, in consideration of the foregoing premises and the mutual covenants
      and obligations set forth herein, the parties hereby agree as
      follows.

    

    ARTICLE
      1

    

    1.       
      Definitions.
      Capitalized
      terms used but not defined herein shall have the meaning ascribed to them in
      the
      Agreement.

    

    ARTICLE
      2

    

    2.       
      Amendment
      of the Agreement.
      The
      Agreement is hereby amended as set forth in this Article 2.

    

    2.1       
      Amendment
      of Article II - Grant.
      Article
      II of the Agreement is hereby amended as set forth herein.

    

    2.1.1       
      Amendment
      of Paragraph 2.2.
      Paragraph
      2.2 of the Agreement is hereby deleted and replaced with the following
      text:

    

    “2.2
      [RESERVED]”

    

    2.1.3       
      Amendment
      of Paragraph 2.3.
      Paragraph
      2.3 of the Agreement is hereby deleted and replaced with the following
      text:

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        29

        
          

        

      

      
        
        

      

    

     

    “2.3
      Except as otherwise specifically set forth herein, the rights granted under
      Paragraph 2.1 hereof shall be and remain exclusively granted to LICENSEE and
      shall continue until the end of the term or terms for which any Patent Rights
      are issued, unless sooner terminated as provided herein. Without limiting the
      generality of the foregoing, upon a failure of LICENSEE to pay the License
      Maintenance Fees due hereunder, the rights granted under Paragraph 2.1 hereunder
      shall convert to non-exclusive upon written notice from M.I.T. to LICENSEE.
      The
      right to convert the rights granted hereunder to non-exclusive shall not be
      in
      limitation of any other rights that M.I.T. may have hereunder or at law upon
      such a failure by LICENSEE to pay the License Maintenance Fees hereunder.”

    

      2.1.3       
      Amendment
      of Paragraph 2.4.
      Paragraph
      2.4 of the Agreement is hereby deleted and replaced with the following
      text:

    

    “2.4
      [RESERVED]”

    

    2.1.4       
      Amendment
      of Paragraph 2.8.
      Paragraph
      2.8 of the Agreement is hereby deleted and replaced with the following
      text:

    

    “2.8
      LICENSEE shall have the right to enter into sublicenses for the rights,
      privileges and licenses granted hereunder. Such sublicenses shall contain
      provisions enabling LICENSEE to fulfill its obligations to M.I.T. hereunder.”

    

    2.1.5       
      Amendment
      of Paragraphs 2.9 and 2.10.
      Paragraphs
      2.9 and 2.10 of the Agreement are hereby deleted and replaced with the following
      text:

    

    “2.9
      [RESERVED]

    

    2.10
      [RESERVED]” 

    

    2.2       
      Amendment
      of Article III - DUE DILIGENCE.
      Article
      III of the Agreement is hereby amended as set forth herein.

    

    2.2.1       
      Amendment
      of Paragraph 3.1.
      Paragraph
      3.1 of the Agreement is hereby deleted and replaced with the following
      text:

    

    “3.1
      LICENSEE shall use reasonable commercial efforts to bring one or more Licensed
      Products to market through a thorough, vigorous and diligent program for
      exploitation of the Patent Rights. Commercially reasonable efforts by LICENSEE
      to grant sublicenses to companies that LICENSEE reasonably believes are engaged
      or will engage in such activities shall be sufficient to satisfy LICENSEE’s
      obligations hereunder.”

    

    2.2.2       
      Amendment
      of Paragraph 3.2.
      Paragraph
      3.2 of the Agreement is hereby deleted and replaced with the following
      text:

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    
      
        
        

      

      
        30

        
          

        

      

      
        
        

      

    

     

    “3.2
      [RESERVED]”

    

    2.3       
      Amendment
      of Article VII - INFRINGEMENT.
      Article
      VII of the Agreement is hereby amended as set forth herein.

    

    2.3.1       
      Amendment
      of Paragraph 7.5.
      Paragraph
      7.5 of the Agreement is hereby deleted and replaced with the following
      text:

    

    “7.5
      In
      the event that a declaratory action alleging invalidity or noninfringement
      of
      any of the Patent Rights shall be brought against LICENSEE, and LICENSEE fails
      to take reasonable steps to defend such action in a timely manner, M.I.T. (or
      Whitehead), at its option, shall have the right to intervene and take over
      sole
      defense of such action at its own expense.”

    

    ARTICLE
      3 

    CONFIRMATION
      OF VALIDITY AND EFFECTIVENESS

    

    3.       
      Confirmation
      of Validity and Effectiveness.
      Except
      as
      otherwise specifically set forth herein, the parties hereby confirm the validity
      and continued effectiveness of the Agreement.

    

    

    IN
      WITNESS
      WHEREOF, the parties have hereunto set their hands and duly executed this Second
      Amendment to License Agreement as of the Effective Date.

     

    
      MASSACHUSETTS
        INSTITUTE OF TECHNOLOGY

      

      
        	 	
                By:

              	
                 /s/
                  Lita L. Nelsen

              
	 	
                Name:

              	
                 Lita
                  L. Nelsen

              
	 	
                Title:

              	
                 Director,
                  Technology Office

              

      

      

      

      

      WHITEHEAD
        INSTITUTE

      

      
        	 	
                By:
                  

              	
                /s/
                  John Pratt

              
	 	
                Name:

              	
                 John
                  Pratt 

              
	 	
                Title:

              	
                 Vice
                  President

              

      

      

      

      ARIAD
        PHARMACEUTICALS, INC.

      

      
        	 	/s/
                Fritz Casselman
	 	
                By:
                  

              	
                Fritz
                  Casselman

              
	 	 	
                Senior
                  Vice President and

              
	 	 	
                Chief
                  Business Officer

              

      

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 24b-2 of the Securities Exchange Act of
        1934.

    

     

    31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]